Single copy human artificial chromosome (HAC) vectors and methods of preparation and use thereof

WO2024226178A3PCT designated stage expired Publication Date: 2024-11-28THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/018885
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-08
Filing Date
2024-03-07
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The development of human artificial chromosomes (HACs) has been hindered by the multimerization and uncontrolled rearrangement of initial DNA constructs, limiting their application in synthetic biology and therapeutic contexts due to the need for improved methods of preparation.

Method used

A method for creating a human artificial chromosome (HAC) lacking repetitive centromere DNA, comprising one or more genomic loci with a coding and non-coding sequence, and utilizing transformation-associated recombination (TAR) with a first vector for acquiring CENP-A chromatin and a second vector for genomic loci, enabling efficient formation of stable, single-copy HACs that replicate and segregate independently of natural chromosomes.

Benefits of technology

This approach allows for the formation of stable, single-copy HACs that function as autonomous chromosomes, facilitating faithful chromosome engineering and potential applications in biomedicine and industrial uses by avoiding the issues of multimerization and rearrangement.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024018885_28112024_PF_FP_ABST
    Figure US2024018885_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates, in part, to human artificial chromosome (HAC), methods of preparation thereof, and methods of using same. In certain embodiments, the HACs of the present disclosure exist as monomers and are stably transmitted as a single copy.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]Attorney Docket No.046483-7423WO1(03465) TITLE OF THE INVENTION Single Copy Human Artificial Chromosome (HAC) Vectors and Methods of Preparation and Use Thereof CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No.63 / 489,085, filed March 8, 2023, which is incorporated herein by reference in its entirety. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT This invention was made with government support under HG012445, and GM130302 awarded by the National Institutes of Health, W911NF-17-2-0092 awarded by the Army Research Laboratory - Army Research Office, and 1840301 awarded by the National Science Foundation. The government has certain rights in the invention. REFERENCE TO AN ELECTRONIC SEQUENCE LISTING The XML filed named “046483-7423WO1 - Sequence Listing.xml” created on March 6, 2024, comprising 2.28 MB, is hereby incorporated herein by reference in its entirety. BACKGROUND Yeast artificial chromosomes (YACs) are typically 0.1-1 Mbp and have enabled triumphs of molecular biology, including the cloning of large disease genes and the generation of entire synthetic prokaryotic genomes. They have also provided the foundation for the generation of entirely synthetic budding yeast chromosomes. The “writing” of new chromosomes, or even entire genomes, is an aspiration for synthetic biologists working in diverse eukaryotes, including in mammalian and plant systems. Human artificial chromosomes (HACs) were developed 25 years ago and paved the way for their deployment for applications in many eukaryotic systems where one key chromosomal locus, the centromere, is larger and is functionally defined not by a particular sequence but by an array of nucleosomes. - 1 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) Unlike YACs, de novo formation of HACs has obligatorily involved multimerization of the initially input DNA construct (i.e., typically 100-200 kb bacterial artificial chromosomes [BACs]), often creating functional HACs with ~50 multimers. The multimerization and the uncontrolled rearrangement of the input DNA that accompanies it during the early steps of HAC formation has severely hindered their development towards their broader promise for synthetic biology and therapeutic applications. There is a need for improved HACs and better methods of preparing the same. The present disclosure addresses this need. BRIEF SUMMARY In one aspect, the disclosure provides a human artificial chromosome (HAC) lacking repetitive centromere DNA, wherein the HAC comprises one or more genomic loci comprising a coding sequence and a non-coding sequence, wherein the one or more genomic loci comprise no more than one focus of CENP-A nucleosomes, and wherein the HAC replicates and segregates in a host cell independently of a natural chromosome of the host cell. In another aspect, the disclosure provides a method for preparing the human artificial chromosome (HAC) of the disclosure. In certain embodiments, the method comprises performing transformation-associated recombination (TAR) comprising a first vector comprising a region for acquiring CENP-A chromatin and a second vector comprising one or more genomic loci. In another aspect, the disclosure provides a cell comprising the human artificial chromosome (HAC) of the disclosure. In another aspect, the disclosure provides a method of treating, preventing, and / or ameliorating a disease in a subject in need thereof. In certain embodiments, the method comprises administering to the subject the human artificial chromosome (HAC) of the disclosure or the cell of the disclosure. BRIEF DESCRIPTION OF THE FIGURES The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments of the present application. - 2 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) FIGs.1A-1D: A 760 kb YAC construct with the necessary components for HAC formation was generated via TAR cloning. FIG.1A: Schematic of YAC construct, Mm-4q21LacO, that was formed to generate single copy HACs. FIG.1B: PCR used to validate the construct was performed on a total of 35 yeast strains of which 9 had positive bands in all three PCR reactions. FIG.1C: Junction PCR of the yeast strain containing YAC-Mm-4q21LacO. FIG.1D: Draft assembly of YAC-Mm-4q21LacO. Sequencing reads aligned to the YAC construct confirm presence of all components of the YAC except for the LacO array. A separate alignment of reads to the LacO array while allowing for multiple alignments confirmed the presence of the LacO array. FIGs.2A-2B: Yeast fusion approach is effective for delivering large DNA constructs in U2OS and HT1080. FIG.2A: Schematic of approach to test for successful yeast fusion. FIG.2B: Examples of successful yeast fusion with mCherry expression as well as the proportion of cells showing mCherry expression. The proportion of cells that were mCherry positive for each cell line is noted. Bar, 10 µm. FIGs.3A-3D: 760 kb HAC constructs efficiently acquire centromeres and exist as autonomous chromosomes. FIG.3A: Schematic of approach to generate a HAC. FIG.3B: Representative images of a single-copy HAC generated in HT1080 and U2OS cells. Insets: 5x magnification. Bar, 5 µm. FIG.3C: Quantification of proportion of “small HACs” (FISH signal spans less than 1 µm), “large HACs” (FISH signal spans greater than 1 µm), “integrations” and “no signal” spreads generated from HAC formation assays. The mean (+ / - SD) is shown. FIG. 3D: Comparison of size of a HAC made from YAC-Mm-4q21LacOand a multimerized HAC made from 4q21 BACLacO. Both HACs are shown at the same scale. Coloring is identical to what is shown in the merged images. Bar, 1 µm. FIG.4: Schematic juxtaposing the approach to generate HACs in prior generations and the approach described herein. FIGs.5A-5E: YAC-Mm-4q21LacO-based HACs are inherited as autonomous chromosomes with functional kinetochores and robust CPC recruitment. FIG.5A: Representative image of a single copy HAC that has been isolated in a monoclonal cell line. Inset: 5x magnification. Bar, 5 µm. FIG.5B: Quantification of fraction of spreads with a HAC in monoclonal cell lines. The mean (+ / - SD) is shown. Colors indicate individual HAC lines that were assessed in HAC retention assays. Red, orange, green and blue correspond to HAC clones - 3 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) 1, 2, 3, and 5. FIG.5C: Quantification of HAC loss rate after culturing without selection for 30 days. The mean (+ / -SD) is shown. Experiments are color coded to correspond to the clones shown in panel B. Grey shading indicates the range of loss rates for prior generations of HACs. FIG.5D: Representative image of HACs synchronized in mitosis showing Aurora B and ACA. The image shows 80.2 µm z-projected stacks. Inset: 5x magnification. Bar, 5 µm. FIG.5E: The radial position of HACs was measured relative to endogenous centromeres. The position of 20 HACs, each endogenous centromere and the center of DNA mass was measured. The distance between HAC or endogenous centromere and the center of DNA mass was calculated. The distance of each HAC from the center was normalized based on the total length across (i.e., the diameter) of mitotic chromosomes. The inner black circle represents the mean radial position of endogenous centromeres, while the dotted line represents one standard deviation from the mean. FIGs.6A-6E: Sequencing reveals elements incorporated into the M. mycoides filler, integrity at the single nucleotide level, a lack of detectable integration of natural yeast chromosomes into the human genome, but coverage biased against the AT-rich filler DNA. FIG. 6A: Illumina sequencing reads derived from Clone 2 and Clone 6 genomic DNA subjected to a serial enrichment strategy were aligned to the YAC-Mm-4q21LacOsequence and visualized in the UCSC Genome Browser. Analysis confirms that the two genes incorporated into the HAC (NeoR and mCherry) are present. Coverage of the HAC was incomplete, omitting significant portions of the extremely AT-rich M. mycoides filler DNA. The low degree of sequence coverage observed throughout the M. mycoides in combination with the robust signal observed in the cytological experiments, both in yeast (as a YAC) and human cells (as a HAC), supports the notion that a very strong sequencing bias influences coverage. Indeed, sequence coverage closely coincide with GC content. The coverage paucity is, thus, most likely due to high sequencing bias resulting from its average GC content of 25%. For future designs of HAC constructs where complete sequence coverage in the context of a complex genome (such as a mammalian genome) is a goal, filler with GC content that is in the realm of most endogenous chromosome sequences, which is ~60%, would likely offer a benefit. Snipgenie was used to assess clone-specific SNPs and indels located within the contiguous regions denoted by black bars, resulting in no calls and further suggesting sequence integrity at the single nucleotide level. Note the unique regions of the HAC can be unambiguously assigned; whereas, the 4q21 reads could be derived from the native locus as well as the HAC locus. FIG.6B: A contiguous stretch of high sequence coverage from the - 4 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) same data in FIG.6A, which was selected for close analysis with Snipgenie, visualized in the Integrated Genomics Viewer. Light grey denotes a perfect match; whereas, an alternately colored line denotes mismatch relative to the reference. Note that the three mismatches appear in both clones, suggesting inheritance from the parent YAC-Mm-4q21LacO, followed by sequence stability through YAC-Mm-4q21LacOHAC formation and maintenance. FIGs.6C-6D: Coverage mapping to the YAC-Mm-4q21LacOreference from 556,800-557,800 (FIG.6C) and 752,220- 753,920 (FIG.6D). This region in panel FIG.6C was chosen for display since it contains the neomycin resistance gene (NeoR) coding sequence and the region in panel FIG.6D for display since it contains the tandem dimer mCherry (tdmCherry) coding sequence (ORFs denoted with rectangles above each plot). Coloring is as in panel FIG.6B. The apparent mismatches are a consequence of lower coverage in these regions relative to that shown in panel FIG.6B and do not meet criteria that Snipgenie requires to call SNPs. FIG.6E: Read counts of unenriched libraries derived from Clone 1, Clone 2, Clone 6, and Clone 8 mapping to the YAC-Mm-4q21LacOreference (minus 4q21) and to the Saccer3 yeast genome (minus the rDNA locus and an adjacent region that maps to a 28S human rDNA gene) per kilobase of queried reference per million mapped reads (RPKM). Statistical analysis was performed with a one-tailed, Welch’s unpaired T- test. The mean (+ / - SD) is shown. ** denotes p<0.01. FIGs.7A-7B: 3-dimensional localization of HACs in monopolar mitotic cells. FIG.7A: Mitotic chromosomes commonly overlap upon z-dimensional projections but are separable upon analysis of individual z-stacked images. This is especially important since DAPI staining is so heavily dominated by the natural chromosomes that are ~100-fold larger than single-copy HACs. ACA signal brightness was increased relative to 2D to increase visibility without z-projection. Three native chromosomes (labeled A, B and C) are immediately adjacent or overlapping to the HAC in the x and y dimensions but are ~1 µm from the HAC in the z dimension. The close proximity of these chromosomes can account for the DAPI staining seen near to the HAC. In the z-stack of maximal Aurora B intensity, Aurora B from the HAC or natural chromosomes is labeled HAC, A, B or C and centromere double dots are labeled with HAC’, HAC’’, A’, A’’ B’, B’’, C’ or C’’. Additionally, the outlines of these chromosomes based on DAPI staining are shown. A z-projected image of all 8 stacks and all centromeres labeled is shown below the individual z-stacks. The peak Aurora B fluorescence is found in the following z-stack images: HAC, 2; A, 8; B, 8; C, 7. The peaks of the two ACA foci for each centromere are found in the - 5 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) following z-stack images: HAC’, 1; HAC’’, 3; A’, 8, A’’, 8; B’, 8, B’’, >8; C’, 7; C’’, 8. FIG.7B: Immunoblot of whole cell lysate using affinity purified ACA antibody shows two bands at the expected size for CENP-B and CENP-A. FIGs.8A-8C: YAC-Mm-4q21LacOHACs are functional as single copy DNA. FIG.8A: Schematic of approach used to enrich single copy HACs. FIG.8B: Representative image of HACs isolated by sucrose gradient with either a single or two foci of LacO. The proportion of HACs with a single or two foci is noted. HACs with two LacO foci also had two CENP-A foci suggesting that they are mitotic. Bar, 1 µm. FIG.8C: Representative image of a multimerized HAC from mitotic chromosome spreads. Bar, 1 µm. FIGs.9A-9D: Quantification of CENP-A and LacO distances show distinct localization and H3K9Me3 is present on HACs. FIG.9A: A260 measurements of fractions collected from a sucrose gradient from top (fraction 1) to bottom (fraction 14) as well as pelleted nuclei (fraction 15). Fraction 15 was diluted 33.3x relative to other samples to acquire a reading in the measurable range (dilution corrected values are plotted). FIG.9B: Enrichment of HAC DNA compared to endogenous chromosomal DNA. The HAC DNA concentration is also shown. FIG. 9C: Three-dimensional Z-stacks were processed using a maximum intensity projection algorithm into a two-dimensional image containing pixels of highest intensity from every slice of the Z- stack. Distances were measured between CENP-A and LacO from the pixels that had the maximum quantified intensity for each respective fluorescent signal (Mean = 0.13 μm, SD = 0.07 μm, N = 48). A one sample t-test using a hypothetical mean of 0, denoting that CENP-A and LacO are not distinctly localized, was performed. The t-test result indicates that the mean is significantly different from 0 (P < 0.0001), suggesting distinct localization. FIG.9D: H3K9Me3 was present on 21 / 26 HACs, further confirming the presence of the inner centromere on the HAC. Bar, 1 µm. FIGs.10A-10I: YAC-Mm-4q21LacO-based HACs are intact 760 kb circles with similar chromatin stretching properties as natural chromosomes. FIG.10A: Southern bot analysis of the indicated HAC lines using a LacO probe. The multimerized HAC line was diluted 20-fold in HT1080 cells to reduce signal relative to the YAC-Mm-4q21LacO-based HAC so that they could be in a similar range of detection. FIG.10B: Schematic showing extent of stretching HACs in the experiments (panels FIGs.10D-10H), with indicated regions detected by FISH. The number of foci shown is in the range predicted by prior stretching experiments with natural chromosomes, - 6 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) with actual outcomes measured in panels FIGs.10C-10G and FIGs.9A-9D. FIG.10C: Representative images of a stretched YAC with both the 4q21 and M. mycoides sequence labeled via FISH compared to endogenous 4q21 in asynchronous cells. Bar, 1 µm. FIG.10D: Representative images of an unstretched and stretched HAC with both the 4q21 and M. mycoides sequence labeled via FISH compared to endogenous 4q21 in asynchronous cells. Bar, 1 µm. FIG. 10E: Quantification of the length of 4q21 FISH in the YAC, HAC and the endogenous chromosome after stretching chromatin in asynchronous cells. The mean (+ / - SD) is shown. p< 0.001 and p < 0.05 based on an unpaired, two-tailed t-test. FIG.10F: Quantification of the number of foci from 4q21 FISH in the YAC, HAC and in the endogenous chromosome after stretching chromatin in asynchronous cells. The mean (+ / - SD) is shown. p values > 0.05 based on an unpaired, two-tailed t-test and is marked as not significant (n.s.). FIG.10G: Representative images of a stretched HAC with both the 4q21 and M. mycoides sequence labeled via FISH after enriching for cells in metaphase. Bar, 1 µm. FIG.10H: Quantification of the number of foci from 4q21 FISH in the HAC and the endogenous chromosome after stretching chromatin and enriching for cells in metaphase. The mean (+ / - SD) is shown. p < 0.0001 based on an unpaired, two-tailed t-test. FIG.10I: Model illustrating how construct size influences HAC formation outcomes. Single-copy BAC-based HACs have never been isolated and are shown as too small to harbor a functional inner centromere. FIG.11: Southern analysis comparing HACs to the parental cell line as a control. The multimerized HAC line was diluted 20-fold in HT1080 cells to reduce signal relative to the YAC-Mm-4q21LacO-based HAC. FIGs.12A-12D: Representative examples of the HAC after physical stretching. FIG. 12A: 4q21 signal is typically more diffuse compared to M. mycoides signal suggesting that the two types of DNA have distinct chromatin properties. FIG.10B: Quantification of Mm FISH foci in experiment shown in FIG.10C and FIG.10G. FIG.10C: Representative images of stretched endogenous 4q21 labeled via FISH after enriching for cells in metaphase. FIG.10D: Quantification of length of 4q21 in experiment shown in FIG.10D and FIG.10G. FIG.13: Quantification of CENP-A intensity in HAC metaphase chromosome spreads in a polyclonal line compared to 3 isolated HAC lines. Quantification of the intensity of a CENP-A at HACs relative to the intensity at endogenous centromeres. Each point represents one HAC. The measured intensities for each HAC line were: polyclonal: 0.20, 0.24, 0.61, 0.74, 0.44, 0.77, - 7 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) 0.60, 0.86, 0.30, 1.28; clone 1: 1.48, 1.27, 0.83, 1.53, 0.53, 0.92, 0.61, 0.91, 0.31, 1.22; clone 2: 0.98, 0.78, 0.89, 0.66, 0.95, 1.06, 0.79, 0.32, 0.56, 0.37; clone 8: 0.54, 0.51, 0.37, 0.88, 0.34, 0.35, 0.74, 0.77, 0.53, 0.39. The mean (+ / - SD) is shown. p < 0.05, n.s, and n.s. based on an unpaired, two-tailed t-test compared isolated HAC lines to the polyclonal line. FIG.14: HACs are found in the nucleus in interphase cells. Representative image from clone 8 IF-FISH showing HAC inside of nucleus. Inset: 3x magnification. Bar, 5 µm. FIGs.15A-15C: HA-LacI-HJURP is delivered to recipient mammalian cells via spheroplast fusion. FIG.15A: HA(1x)-LacI-HJURP was inserted into a vector containing the TPI1 promoter and CYC1 terminator to drive high, constitutive expression in yeast carrying an integration of this vector. Subsequently, this vector was digested with PacI and ethanol precipitated.100 ng was used to electroporate the YAC-Mm-4q21LacOstrain. Electroporated yeast were recovered overnight in 1 ml 1M sorbitol : 1 YPD solution before plating on SD-His- Ura plates. This strain was screened by junctional PCR, Sanger sequencing of the expression cassette, and ONT sequencing. ONT data was aligned with Epi2Me against a concatenated genome consisting of the YAC and the Saccer3 genome with the entire integrating vector inserted just upstream of the native TPI1 promoter, which is located in chromosome IV. Alignments were visualized in the Integrated Genomics Viewer. Shown is the alignment track corresponding to the recombinant Saccer3 chromosome IV from 565,000 to 555,000 in line with the above graphical depiction. FIG.15B: Experimental design for FIG.15C. The recombinant pTPI1>HA-LacI-HJURP; YAC-Mm-4q21LacOor its parent (YAC-Mm-4q21LacO) strain were fused with U2OS cells harboring an integrated LacO array and processed 12 hours later for HA IF to ascertain expression and delivery of HA-LacI-HJURP post fusion. FIG.15C: Representative images of fused cells from the experiment described in B. U2OS cells derived from fusions with either yeast strain contain nuclei in the cytoplasm. Only fusion with the pTPI1>HA-LacI-HJURP; YAC-Mm-4q21LacOstrain results in detectable HA signal, which remains proximal to the yeast nuclei. FIGs.16A-16B: Fusions of U2OS HiLo cells with the pTPI1>HA-LacI-HJURP; YAC- Mm-4q21LacO result in HAC formation. FIG.16A: Depiction of the HAC formation assay. Yeast treated with zymolyase-20T to remove the cell wall are added to 300,000 U2OS HiLo cells at a 300:1 ratio and then incubated in 45% PEG2000, 10% DMSO in 75 mM HEPES (pH 7.5) for 5 minutes. Three days post fusion, cells are cultured in media containing 267 µg / ml G418 for - 8 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) 8 days to eliminate transient and non-fusion events before expanding at 100-150 µg / ml G418. Once cells reach near confluence in a 10-cm plate, they are passaged to two plates for freeze down and CENP-A IF, M. mycoides FISH of chromosome spreads. FIG.16B: 20 spreads were scored per replicate, and the fraction of the indicated events is represented as a stacked bar. HACs were called if 1) there were two CENP-A foci with the brightest being ≥ 70% of the intensity of a native CENP-A focus, 2) the distance between foci was 400-1000 nm, and 3) exhibited encompassing M. mycoides FISH signal. Shown is a representative HAC-containing spread. Integrations were called for spreads containing a natural chromosome in which two FISH foci could be seen distal to the centromere on each chromosome arm. No signal was designated for instances in which neither of the aforementioned could be confidently called. A one-tailed t- test was conducted. *** corresponds to p<.001. DETAILED DESCRIPTION OF THE INVENTION Reference will now be made in detail to certain embodiments of the disclosed subject matter, examples of which are illustrated in part in the accompanying drawings. While the disclosed subject matter will be described in conjunction with the enumerated claims, it will be understood that the exemplified subject matter is not intended to limit the claims to the disclosed subject matter. Throughout this document, values expressed in a range format should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. For example, a range of "about 0.1% to about 5%" or "about 0.1% to 5%" should be interpreted to include not just about 0.1% to about 5%, but also the individual values (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.1% to 0.5%, 1.1% to 2.2%, 3.3% to 4.4%) within the indicated range. The statement "about X to Y" has the same meaning as "about X to about Y," unless indicated otherwise. Likewise, the statement "about X, Y, or about Z" has the same meaning as "about X, about Y, or about Z," unless indicated otherwise. In this document, the terms "a," "an," or "the" are used to include one or more than one unless the context clearly dictates otherwise. The term "or" is used to refer to a nonexclusive "or" unless otherwise indicated. The statement "at least one of A and B" or "at least one of A or - 9 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) B" has the same meaning as "A, B, or A and B." In addition, it is to be understood that the phraseology or terminology employed herein, and not otherwise defined, is for the purpose of description only and not of limitation. Any use of section headings is intended to aid reading of the document and is not to be interpreted as limiting; information that is relevant to a section heading may occur within or outside of that particular section. All publications, patents, and patent documents referred to in this document are incorporated by reference herein in their entirety, as though individually incorporated by reference. In the methods described herein, the acts can be carried out in any order, except when a temporal or operational sequence is explicitly recited. Furthermore, specified acts can be carried out concurrently unless explicit claim language recites that they be carried out separately. For example, a claimed act of doing X and a claimed act of doing Y can be conducted simultaneously within a single operation, and the resulting process will fall within the literal scope of the claimed process. Description The ability to synthesize large DNA assemblies has led to milestone achievements in prokaryotic systems and budding yeast chromosome biology. Chromosomes in mammals and many other eukaryotes control their own inheritance through an epigenetic locus: the centromere. Harnessing centromere epigenetics permits human artificial chromosome (HAC) formation but is not sufficient to avoid rampant multimerization of the initial DNA molecule that is introduced. In one aspect, the present disclosure relates to a method for efficient formation of stable, single copy HACs. Their single-copy nature is achieved by starting with a large (i.e., megabase scale) HAC construct that is sufficiently large to house the distinct chromatin types present at the inner and outer centromere. These HACs harbor full centromere function without the need to initially multimerize, thus permitting faithful chromosome engineering in the context of metazoan cells. De novo HACs, including the HACs of the present disclosure, are the only viable platform to generate a new mammalian chromosome where the entire DNA sequence can be designed in the lab. This presents an extremely wide horizon of possibilities for downstream biological and applied uses. In one aspect, the present disclosure describes a system to create HACs that faithfully exist in their functional form as a single copy. The advances are centered on the portion of the chromosome, the centromere, that controls segregation of the HAC at cell - 10 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) division. Single copy HAC formation requires establishment of a high local density of CENP-A nucleosomes that can self-propagate alongside natural centromeres, but this is not sufficient for centromere function. Rather, an entirely different chromatin domain, the inner centromere, must function in mitotic quality control and control of sister chromatid cohesion. The HACs formed from the YAC Mm-4q21LacOare large enough to harbor robust CENP-A arrays and inner centromeric chromatin. The overhauled HAC cell delivery approach via spheroplast fusion, was necessary because the initial construct is too large to reliably purify and transfect, and has the benefit of being far more efficient than HAC construct transfections. This fortuitous side-product of moving to spheroplast fusion-based delivery has important practical implications for the development and testing of specific features of HACs. In prior generations of HACs, rigorous testing of a modest number of constructs or cell lines requires the isolation and subsequent cytological assessment of hundreds of cell lines that are cloned weeks after initial HAC construct transfection, since the initial selected cell populations are so sparse and HAC formation is so inefficient. With YAC Mm-4q21LacO, high HAC formation efficiency can be measured in rapidly generated cell populations, without the requirement to generate any clonal lines. To measure the prior generation HACs with a similar level of repetition and statistical power as in one of the YAC Mm-4q21LacOexperiments with four different conditions, as described herein, would have required generating a minimum of 240 cell lines with prior generations of HACs. The YAC Mm- 4q21LacOapproaches reported herein eliminate the initial need for isolating hundreds of cell lines at the outset for each new derivative. Further, the innovations in HACs described herein promise to bring artificial / synthetic chromosomes towards their potential in delivering useful cargos for biomedicine and industrial applications. Since both the CENP-A-based epigenetic centromere specification mechanism and the inner centromeric dimensions and molecular constituency (e.g., sister centromere cohesion components and CPC) are common to diverse eukaryotic species, including in many agriculturally important plants, it is envisioned that YAC Mm-4q21LacO-based artificial chromosomes will be readily modified and extended into many useful biological systems. The YAC Mm-4q21LacOsystem also extends the capacity for HACs to advance the understanding of natural chromosomes. In other words, using HACs as testing grounds for - 11 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) designing what nature has evolved to ensure the stability of the genome between cell divisions and from one organismal generation to the next, as well as designing the functional features that govern chromosome “outputs” in gene expression programs and epigenetic regulation. For instance, the methodology described herein to isolate an intact HAC from nuclei notably extends HAC technology as attractive vehicles with to visualize and probe principles of chromatin organization on individual interphase chromosomes. In summary, the advancements made in this study to HAC design, delivery, formation, and function will expedite both discovery-based and applied genome science. Definitions The term “about” as used herein can allow for a degree of variability in a value or range, for example, within 10%, within 5%, or within 1% of a stated value or of a stated limit of a range, and includes the exact stated value or range. The term “cell fusion method” or “fusion” or “fusing” refers to a method in which two or more cells are combined to form a single hybrid cell which contains all or part of at least the nucleic acid content of each individual cell. Fusion may be accomplished by any method of combining cells under fusogenic conditions well known in the art. For example, PEG is the most widely used chemical reagent to trigger cell fusion during development of monoclonal antibodies. The cell fusion can be also achieved by the physical method using electric pulse. In addition, the biological method for cell fusion is induced by the inactivated virus. The term "cell therapy," "adoptive cell therapy," "cellular therapy," or "immune cell therapy" as used herein means a form of therapy that involves the use of cells (e.g., immune cells) in the prevention and / or treatment of a disease. Examples of cell therapies include allogeneic stem cell transplantation, CAR-T, CAR-NK, macrophage-CAR, TCR-T and TIL therapies, and T cell vaccination protocols. One form of cell therapy is immune cell therapy, e.g., CAR-T cell therapy. Because bispecific T cell engagers also engage T cells, they are also considered a form of immune cell therapy. As used herein, the term "centromere" means the DNA sequence that normally is present at the junction between the two arms of a chromosome and is associated with the structure to which the spindle fibers attach during mitosis. For purposes of the present invention, a centromere is identified by its function of providing stable segregation during cell division of a - 12 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) nucleic acid sequence linked to the centromere. While it is recognized that the spindle fibers likely do not attach directly to the DNA sequence contained in a centromere but, instead, attach to a nucleoprotein complex formed, in part, by the DNA sequence, no mechanism is proposed herein as to how a centromere functions. The term "centromeric fragment" is used herein to mean a portion of a chromosome containing a centromere. As disclosed herein, a centromeric fragment can be obtained, for example, by irradiating a cell at a dose that results in breakage of the chromosomes. As used herein, the terms “coding sequence” mean a polynucleotide sequence that is translated in an organism to produce a protein. The term “coding DNA sequence” is a DNA sequence from which the information for making a peptide molecule, mRNA or tRNA are transcribed. A DNA sequence may be a gene, combination of genes, or a gene fragment. As used herein, the term “comprising” is to be construed as encompassing both “including” and “consisting of”, both meanings being specifically intended, and hence individually disclosed embodiments in accordance with the present invention. Where used herein, “and / or” is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example, “A and / or B” is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein. In the context of the present invention, the terms “about” and “approximately” denote an interval of accuracy that the person skilled in the art will understand to still ensure the technical effect of the feature in question. The term typically indicates deviation from the indicated numerical value by ±20%, ±15%, ±10%, and for example ±5%. As will be appreciated by the person of ordinary skill, the specific such deviation for a numerical value for a given technical effect will depend on the nature of the technical effect. For example, a natural or biological technical effect may generally have a larger such deviation than one for a man-made or engineering technical effect. As will be appreciated by the person of ordinary skill, the specific such deviation for a numerical value for a given technical effect will depend on the nature of the technical effect. For example, a natural or biological technical effect may generally have a larger such deviation than one for a man-made or engineering technical effect. Where an indefinite or definite article is used when referring to a singular noun, e.g. “a”, “an” or “the”, this includes a plural of that noun unless something else is specifically stated. - 13 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) The term “control sequences” refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers. As used herein, a “disease” is a state of health of a subject wherein the subject cannot maintain homeostasis, and wherein if the disease is not ameliorated then the subject's health continues to deteriorate. The terms "donor cell" and "recipient cell" as used in the present disclosure refers to a cell that first carries the vector (i.e., a donor cell) and a cell into which the vector is to be introduced from the donor cell (i.e., a recipient cell), when a human artificial chromosome vector, or template thereof, is to be transferred or introduced. As used herein, the term “DNA” means deoxyribonucleic acid. The term “encode” as used herein refers to the product specified (e.g., protein and RNA) by a given sequence of nucleotides in a nucleic acid (i.e., DNA and / or RNA), upon transcription or translation of the DNA or RNA, respectively. In certain embodiments, the term “encode” refers to the RNA sequence specified by transcription of a DNA sequence. In certain embodiments, the term “encode” refers to the amino acid sequence (e.g., polypeptide or protein) specified by translation of mRNA. In certain embodiments, the term “encode” refers to the amino acid sequence specified by transcription of DNA to mRNA and subsequent translation of the mRNA encoded by the DNA sequence. In certain embodiments, the encoded product may comprise a direct transcription or translation product. In certain embodiments, the encoded product may comprise post-translational modifications understood or reasonably expected by one skilled in the art. The terms “expression vector” and “expression cassette” refer to a nucleic acid molecule capable of directing expression of a particular nucleotide sequence in an appropriate host cell, typically comprising a promoter operatively linked to the nucleotide sequence of interest which is operatively linked to termination signals. It also typically comprises sequences required for proper translation of the nucleotide sequence. The coding region usually encodes a polypeptide(s) of interest but can also encode a functional RNA of interest, for example antisense RNA or a non-translated RNA, in the sense or antisense direction. The expression - 14 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) cassette comprising the nucleotide sequence of interest can be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components. The expression cassette can also be one that is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. Typically, however, the expression cassette is heterologous with respect to the host; i.e., the particular DNA sequence of the expression cassette does not occur naturally in the host cell and was introduced into the host cell or an ancestor of the host cell by a transformation event. The expression of the nucleotide sequence in the expression cassette can be under the control of a constitutive promoter or of an inducible promoter that initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism such as a plant, the promoter can also be specific to a particular tissue, organ, or stage of development. The terms "foreign DNA" and "exogenous nucleic acid sequence" are used interchangeably herein to refer to DNA that is introduced into a target cell from the outside. The term refers to DNA encoding a gene, the expression of which is desired for the purpose of material production, disease treatment, function modification, functional analysis, or the like, or another functional sequence (e.g., a promoter sequence). Such DNA may be allogeneic or xenogeneic. As used herein, the term “gene” should be understood to refer to a unit of heredity. Each gene is composed of a linear chain of deoxyribonucleotides which can be referred to by the sequence of nucleotides forming the chain. Thus, “sequence” is used to indicate both the ordered listing of the nucleotides which form the chain, and the chain itself, which has that sequence of nucleotides. The term “sequence” is used in the similar way in referring to RNA chains, linear chains made of ribonucleotides. The gene may include regulatory and control sequences, sequences which can be transcribed into an RNA molecule, and may contain sequences with unknown function. The majority of the RNA transcription products are messenger RNAs (mRNAs), which include sequences which are translated into polypeptides and may include sequences which are not translated. It should be recognized that small differences in nucleotide sequence for the same gene can exist between different strains of the same type of organism, or even within a particular strain of the organism, without altering the identity of the gene. The terms “gene introduction” or “gene delivery” or “gene transfer” refers to methods or systems for reliably inserting foreign DNA into target cells and include transduction, transfection - 15 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) and transformation. Such methods can result in transient or long term (stable) expression of genes. The term “transduction” refers to the delivery of a DNA molecule to a recipient cell either in vivo or in vitro, via a replication-defective viral vector, such as, e.g., adenoviral vector. The term “transfection” is used to refer to the uptake of foreign DNA by a vertebrate cell. A cell has been “transfected” when exogenous DNA has been introduced across the cell plasma membrane. Transfection can be used to introduce one or more exogenous DNA moieties, such as a plasmid vector and other nucleic acid molecules, into suitable cells. The term refers to both stable and transient uptake of the genetic material. The term “transformation” refers to a process for introducing heterologous DNA into a cell. Transformed cells are understood to encompass not only the end product of a transformation process, but also transgenic progeny thereof. The term “genomic DNA” as used herein is defined as DNA material comprising the partial or full collective gene set carried by an organism, cell, or organelle. The term “heterologous DNA” or “heterologous RNA” refers to DNA or RNA that does not occur naturally as part of the genome or DNA or RNA sequence in which it is present, or in which it is found, a cell or location or locations in the genome or DNA or RNA sequence that differs from that which it is found in in nature. Heterologous DNA or RNA is not endogenous to the cell into which it is introduced, but has been obtained from another cell or synthetically or recombinantly produced. Generally, though not necessarily, such DNA encodes RNA and protein not normally produced by the cell in which the DNA is transcribed or expressed. Similarly exogenous RNA encodes protein not normally expressed in the cell in which the exogenous RNA is present. Heterologous DNA or RNA may also be referred to as foreign DNA or RNA. Any DNA or RNA that one of skill in the art would recognize as heterologous or foreign to the cell in which it is expressed is herein encompassed by the term heterologous DNA or heterologous RNA. Examples of heterologous DNA include, but are not limited to, DNA that encodes a protein, polypeptide, reporter nucleic acid sequence, transcriptional or translational regulatory sequences, selectable or traceable marker protein, such as a protein that confers drug resistance, RNA including mRNA and antisense RNA, and ribozymes. As used herein, the term "human artificial chromosome" or "HAC" means a nucleic acid molecule that 1) forms a centromere, 2) contains an origin of DNA replication, and 3) has a unique cloning site. In particular, the HAC of the present invention contains a nucleic acid sequence encoding a selectable marker, which can be used as a site into which an exogenous - 16 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) nucleic acid sequence can be cloned. Due, in part, to the structural characteristics described above, a HAC is characterized further in that it is stably and autonomously maintained in a host cell and, therefore, is present in both daughter host cells following mitosis of the parental host cell. The term "human chromosome fragment" refers to a partial fragment of a chromosome that is capable of stable replication and distribution as an independent chromosome. The size of such fragment is generally 1 Mb or greater, and it is occasionally 1 Mb or smaller. The term “inducible expression” is used to describe expression that requires interaction of an inducer molecule or the release of a co-repressor molecule and a regulatory protein for expression to take place. The term “constitutive expression” refers to expression which is not usually inducible. The term “non-standard coded DNA” as used herein refers to a sequence of naturally occurring DNA which comprises coding DNA sequence under endogenous conditions (e.g., in mycoplasma), does not comprising coding DNA under certain exogenous conditions (e.g., in a mammalian cell) due to a difference in the codon usage in expression machinery (e.g., UGA codon comprises a stop codon in the standard code, represents a tryptophan codon in mycoplasma). The term “operably linked” as used herein, refers to a nucleic acid which is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. The term “promoter region” refers to a DNA sequence that functions to control the transcription of one or more nucleic acid sequences, located upstream with respect to the direction of transcription of the transcription initiation site of the gene, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription - 17 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, calcium or cAMP responsive sites, and any other nucleotide sequences known to act directly or indirectly to regulate transcription from the promoter. A “recombinant” or “isolated” nucleic acid molecule comprising the various nucleic acid sequences disclosed herein, means a nucleic acid molecule that has been assembled by molecular biological techniques to contain sequences of defined function that are operably linked. The terms “sequence homology,” “percent identity (%),” “sequence identity,” “sequence identity percent,” or “percent identity” in the context of nucleic acid and / or amino acid sequences refers to a quantitative measurement of the similarity between two nucleic acid or amino acid sequences (e.g., DNA, amino acid or otherwise). In general, when referring to “identity,” “homology,” or “similarity” between two different sequences, “identity,” “homology,” or “similarity” is that of an “aligned” sequence. Determined in relation to an “aligned” sequence or “alignment” refers to a plurality of nucleic acid or protein (amino acid) sequences that often contain corrections for missing or additional bases or amino acids compared to the reference sequence. The term “spheroplast fusion” as used herein refers to a cellular process whereby two or more spheroplasts, which are bacterial or fungal cells whose cell walls have been removed through enzymatic treatment, and / or mammalian cells whose cell membranes have been otherwise disrupted, are combined to form a single entity. As used herein, the term "stably expressed" when used in reference to a selectable marker means that the nucleic acid molecule encoding the marker is maintained and expressed in a cell line. In particular, a selectable marker is stably expressed from generation to generation in a cell type that traverses the cell cycle and, ultimately, divides. The ability to stably express a selectable marker in a cell is due to the ability of a HAC to be replicated during the cell cycle and to segregate with a daughter cell during cell division. It is recognized, however, that some cells such as muscle cells generally do not divide. Nevertheless, a selectable marker is considered to be stably expressed in a non-dividing cell if the HAC containing the selectable marker is stably and autonomously maintained in the cell and if the selectable marker is expressed as appropriate. In this regard, it is further recognized that the term "stably" when used in reference to the expression of a selectable marker does not necessarily mean that the marker is "always" or - 18 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) "constantly" expressed because expression of a selectable marker is regulated, in part, by the particular gene regulatory elements linked to the marker. For example, a selectable marker containing a promoter that is active only during a particular stage of the cell cycle or that is induced only when activated by a particular regulatory factor, nevertheless is considered stably expressed if the selectable marker is expressed at the appropriate time. Thus, a "stably expressed" marker is stably expressed with reference to the particular regulatory elements linked to the marker. The term “substantially” as used herein refers to a majority of, or mostly, as in at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more, or 100%. The term “substantially free of” as used herein can mean having none or having a trivial amount of, such that the amount of material present does not affect the material properties of the composition including the material, such that the composition is about 0 wt% to about 5 wt% of the material, or about 0 wt% to about 1 wt%, or about 5 wt% or less, or less than, equal to, or greater than about 4.5 wt%, 4, 3.5, 3, 2.5, 2, 1.5, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, or about 0.001 wt% or less. The term “substantially free of” can mean having a trivial amount of, such that a composition is about 0 wt% to about 5 wt% of the material, or about 0 wt% to about 1 wt%, or about 5 wt% or less, or less than, equal to, or greater than about 4.5 wt%, 4, 3.5, 3, 2.5, 2, 1.5, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, or about 0.001 wt% or less, or about 0 wt%. The terms “substantially identical” or “substantial identity,” in the context of two or more nucleic acids, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides that are the same (i.e., at least about 60%, in certain embodiments at least about 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity over a specified region), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. This definition, when the context indicates, also refers analogously to the complement of a sequence. In certain embodiments, the substantial identity exists over a region that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides in length. The term “vector” refers to any genetic element, such as a plasmid, phage, transposon, cosmid, chromosome, virus, virion, etc., which is capable of replication when associated with the - 19 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) proper control elements, such as a helper virus, and which can transfer gene sequences between cells. Thus, the term includes cloning and expression vehicles, as well as replication-defective viral vectors. The term “vehicle” as used herein refer to a carrier and / or inert medium in which an active agent (e.g., nucleic acid) is formulated and / or administered. Human Artificial Chromosome (HAC) Vectors and / or Templates Thereof In one aspect, the present disclosure provides a human artificial chromosome (HAC) lacking repetitive centromere DNA, wherein the HAC comprises one or more genomic loci comprising a coding sequence and a non-coding sequence, wherein the one or more genomic loci comprise no more than one focus of CENP-A chromatin, and wherein the HAC replicates and segregates in a host cell independently of a natural chromosome of the host cell. In certain embodiments, a focus of CENP-A chromatin is a region of the chromosome which has a high local concentration of CENP-A nucleosomes. In certain embodiments, a single focus is resolvable by light microscopy. In some embodiments, the HAC is an isolated HAC. In some embodiments, the HAC is a circular vector. In certain embodiments, the HAC further comprises a sequence of chromosome 4, band 21, long arm (4q21 sequence). In certain embodiments, the 4q21 sequence comprises the focus of CENP-A nucleosomes. In certain embodiments, the 4q21 sequence comprises a region for acquiring CENP-A chromatin. In certain embodiments, the coding sequence comprises one or more sequences encoding one or more polypeptides. In some embodiments, the non-coding DNA sequence comprises a length of at least about 100 kilobases (kb), illustratively, about 100 kb to about 10 megabase (Mb), about 200 kb to about 5 Mb, about 300 kb to about 2.5 Mb, about 400 kb to about 2 Mb, about 500 kb to about 1.5 Mb, about 600 kb to about 1 Mb, and about 700 kb to about 9 kb. In other embodiments, the non-coding DNA sequence comprises a length of at least about 100 kilobases (kb), illustratively, about 100 kb or more, about 200 kb or more, about 300 or more, about 400 kb or more, about 500 kb or more, about 600 kb or more, and about 700 kb or more, about 710 kb or more, about 720 kb or more, about 730 kb or more, about 740 kb or more, - 20 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) about 750 kb or more, about 760 kb or more, about 770 kb or more, about 780 kb or more, and about 790 kb or more. In another embodiment, the non-coding DNA sequence comprises a length of at least about 100 kilobases (kb), illustratively, about 100 kb, about 200 kb, about 300 kb, about 400 kb, about 500 kb, about 600 kb, and about 700 kb, about 710 kb, about 720 kb, about 730 kb, about 740 kb, about 750 kb, about 760 kb, about 770 kb, about 780 kb, and about 790 kb. In certain embodiments, the non-coding DNA sequence comprises about 760 kilobases (kb) or more. In certain embodiments, the non-coding DNA sequence comprises a DNA sequence that shares at least 85%, 90%, or 95% sequence homology with SEQ ID NO:9. In some embodiments, the non-coding DNA sequence comprises the sequence set forth as SEQ ID NO:9. In certain embodiments, the genomic loci further comprises one or more lactose operons (lacO). In certain embodiments, the HAC comprises YAC Mm-4q21LacO. In certain embodiments, YAC Mm-4q21LacOcomprises a DNA sequence that shares at least 85%, 90%, or 95% sequence homology with SEQ ID NO:1. In certain embodiments, YAC Mm-4q21LacOcomprises the construct depicted in FIG.1A and FIG.1D. In certain embodiments, YAC Mm- 4q21LacOis substantially identical to the construct depicted in FIG.1A and FIG.1D. In another aspect, the present disclosure provides a human artificial chromosome (HAC) vector template comprising: (a) a heterologous, non-coding DNA sequence comprising at least about 550 kilobases (Kb); (b) a human genomic DNA sequence; (c) a DNA sequence comprising one or more lactose operon (LacO) sequences, wherein the one or more LacO sequences flank the human genomic sequence; (d) a eukaryotic selection marker; (e) an expression cassette comprising a foreign DNA sequence; and (f) an expression control sequence operably linked to the foreign DNA sequence. - 21 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) In certain embodiments, wherein the heterologous, non-coding DNA sequence comprises about 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or about 10.0 megabases (Mb). In certain embodiments, wherein the heterologous, non-coding DNA sequence comprises less than about 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or about 10.0 megabases (Mb). In certain embodiments, wherein the heterologous, non-coding DNA sequence comprises more than about 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or about 10.0 megabases (Mb). In certain embodiments, the heterologous, non-coding DNA sequence comprises bacterial genomic DNA. In certain embodiments, the bacterial genomic DNA comprises non-standard coded DNA. In certain embodiments, the bacterial genomic DNA is derived from Mycoplasma bacteria. In certain embodiments, the Mycoplasma bacteria is Mycoplasma mycoides. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 85% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 90% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 95% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 96% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 97% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 98% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 99% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares 100% sequence homology with SEQ ID NO:9. In certain embodiments, the human genomic DNA comprises 4q21, or a fragment thereof. In certain embodiments, the template comprises a 10 kb LacO array. - 22 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) In certain embodiments, the eukaryotic selection marker is a yeast selection marker. In certain embodiments, the foreign DNA comprises at least one selected from the group consisting of a eukaryotic gene, a prokaryotic gene, a promoter, and a reporter gene. In certain embodiments, the foreign DNA encodes non-coding RNA, optionally wherein the RNA is selected from the group consisting of microRNA, siRNA, piRNA, snoRNA, snRNA, exRNA, scaRNA, transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs). In certain embodiments, the foreign DNA encodes a protein. In certain embodiments, the protein is mCherry. In certain embodiments, the protein is Holliday junction recognition protein (HJURP). In certain embodiments, the expression cassette is a mammalian expression cassette. In certain embodiments, the template further comprises at least one antibiotic resistance marker. In certain embodiments, the antibiotic resistance marker is a neomycin resistance marker (neoR). In certain embodiments, the HAC comprises YAC Mm-4q21LacO. In certain embodiments, YAC Mm-4q21LacOcomprises a DNA sequence that shares at least 85%, 90%, or 95% sequence homology with SEQ ID NO:1. In certain embodiments, YAC Mm-4q21LacOcomprises the construct depicted in FIG.1A and FIG.1D. In certain embodiments, YAC Mm- 4q21LacOis substantially identical to the construct depicted in FIG.1A and FIG.1D. In another aspect, the present disclosure provides a human artificial chromosome (HAC) vector comprising: (a) a heterologous, non-coding DNA sequence comprising at least about 550 kilobases (Kb); (b) a human genomic DNA sequence; (c) a DNA sequence comprising one or more lactose operon (LacO) sequences, wherein the one or more LacO sequences flank the human genomic sequence; (d) a eukaryotic selection marker; (e) an expression cassette comprising a foreign DNA sequence; and (f) an expression control sequence operably linked to the foreign DNA sequence; and (g) a centromere. - 23 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) In certain embodiments, the human artificial chromosome (HAC) vector is prepared according to the methods of the present disclosure. In certain embodiments, the vector comprises nucleosomes seeded by CENP-A. In certain embodiments, the vector exists as a monomer. In certain embodiments, the vector is stably transmitted as a single copy. In certain embodiments, wherein the heterologous, non-coding DNA sequence comprises about 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or about 10.0 megabases (Mb). In certain embodiments, wherein the heterologous, non-coding DNA sequence comprises less than about 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or about 10.0 megabases (Mb). In certain embodiments, wherein the heterologous, non-coding DNA sequence comprises more than about 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or about 10.0 megabases (Mb). In certain embodiments, the heterologous, non-coding DNA sequence comprises bacterial genomic DNA. In certain embodiments, the bacterial genomic DNA comprises non-standard coded DNA. In certain embodiments, the bacterial genomic DNA is derived from Mycoplasma bacteria. In certain embodiments, the Mycoplasma bacteria is Mycoplasma mycoides. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 85% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 90% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 95% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 96% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 97% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 98% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding DNA sequence comprises a DNA sequence that shares at least 99% sequence homology with SEQ ID NO:9. In certain embodiments, the heterologous, non-coding - 24 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) DNA sequence comprises a DNA sequence that shares 100% sequence homology with SEQ ID NO:9. In certain embodiments, the human genomic DNA comprises 4q21, or a fragment thereof. In certain embodiments, the template comprises a 10 kb LacO array. In certain embodiments, the eukaryotic selection marker is a yeast selection marker. In certain embodiments, the foreign DNA comprises at least one selected from the group consisting of a eukaryotic gene, a prokaryotic gene, a promoter, and a reporter gene. In certain embodiments, the foreign DNA encodes non-coding RNA, optionally wherein the RNA is selected from the group consisting of microRNA, siRNA, piRNA, snoRNA, snRNA, exRNA, scaRNA, transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs). In certain embodiments, the foreign DNA encodes a protein. In certain embodiments, the protein is mCherry. In certain embodiments, the protein is Holliday junction recognition protein (HJURP). In certain embodiments, the expression cassette is a mammalian expression cassette. In certain embodiments, the template further comprises at least one antibiotic resistance marker. In certain embodiments, the antibiotic resistance marker is a neomycin resistance marker (neoR). In certain embodiments, the HAC comprises YAC Mm-4q21LacO. In certain embodiments, YAC Mm-4q21LacOcomprises a DNA sequence that shares at least 85%, 90%, or 95% sequence homology with SEQ ID NO:1. In certain embodiments, YAC Mm-4q21LacOcomprises the construct depicted in FIG.1A and FIG.1D. In certain embodiments, YAC Mm- 4q21LacOis substantially identical to the construct depicted in FIG.1A and FIG.1D. Foreign DNA As indicated elsewhere herein, the terms “foreign DNA” and “exogenous nucleic acid sequence” are used interchangeably herein. In certain embodiments, the exogenous nucleic acid sequence or foreign DNA can be a fragment of genomic DNA, which can be prepared from intact genomic DNA by physical disruption using, for example, irradiation or sonication or by chemical cleavage using, for example, a restriction endonuclease such as a rare cutting - 25 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) endonuclease that cleaves genomic DNA at relatively few sites. A population of HACs containing diverse fragments of genomic DNA prepared from a particular cell type can constitute a genomic library, which can be screened, for example, to identify fragments containing particular genes of interest. Since a HAC can contain a fragment of genomic DNA having several million base pairs, such a genomic library can contain, for example, a complex genetic locus, thereby providing a model system useful for identifying the regulatory regions such as enhancers or silencers that are involved in regulation of gene expression from the locus and the regulatory factors that bind to such regions. Thus, a HAC is useful as a cloning vector and provides the additional advantage that very large fragments of DNA on the order of several million bases can be cloned into and maintained in the HAC. An exogenous nucleic acid sequence also can be inserted into a HAC for the purpose of being expressed. Such an exogenous nucleic acid sequence can be, for example, a particular gene such as the gene encoding dystrophin; or can be a cDNA, which encodes a gene product; or can be a sequence that, when expressed, is complementary to a nucleic acid of interest and acts, for example, as an antisense molecule, which can hybridize to a particular DNA or RNA sequence, or acts as a ribozyme, which can hybridize to and cleave a particular RNA. Thus, a HAC also can be useful as an expression vector and provides the additional advantage that it is stable through numerous rounds of cell division. An exogenous nucleic acid sequence also can include a regulatory element involved in the regulation of gene expression or of translation of a transcript. Such regulatory elements such as a promoter, enhancer, silencer, polyadenylation signal sequence, ribosome entry site, signal peptide encoding sequence, nuclear localization signal encoding sequence and the like are well known in the art and can be inserted into a HAC, as desired, using well known methods of recombinant DNA technology (see, for example, Kriegler, Gene Transfer and Expression: A laboratory manual (W.H. Freeman and Co., New York; 1990), which is incorporated herein by reference). Various types of regulatory elements are available and are selected based on the particular purpose for which a HAC is being constructed. A promoter element, for example, can be constitutive such as the cytomegalovirus promoter or Rous sarcoma virus promoter, or can be inducible such as the metallothionein promotor. In addition, a promoter can be a tissue specific promotor such as the myoD promoter, which is expressed only in muscle cells, or the lck - 26 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) promoter, which is expressed only in T cells, or can be a promoter that is active only during a particular stage of development. Similarly, enhancers can be constitutive or inducible or, like the SV40 enhancer, can be constitutively active and, in addition, can be induced to a higher level of activity. Such gene regulatory elements and translation regulatory elements generally are relatively small and can be synthesized using routine methods of DNA synthesis or can be purchased in vectors from commercial sources. A HAC is characterized, in part, by containing a unique cloning site. As used herein, the term "unique cloning site" means a nucleic acid sequence that can be targeted for insertion of an exogenous nucleic acid sequence. As disclosed herein, a unique cloning site can be, for example, a specific target site such as the loxP sequence, which is a target for the Cre recombinase, or an FLP site, which is a target for the FRP recombinase (see below). The presence of such a cloning site in a HAC allows the site specific integration of an exogenous nucleic acid sequence into the HAC. A unique cloning site also can be a nucleic acid sequence encoding a gene product, provided the nucleic acid sequence is present in a single copy on the HAC. If desired, an exogenous nucleic acid sequence can be cloned into such a single copy nucleic acid sequence present on the HAC using, for example, methods of homologous recombination as disclosed herein. Selectable Markers A selectable marker can confer upon a cell expressing the marker the ability to survive in an environment that otherwise kills cells not expressing the marker. The use of such a selectable marker requires that a mutant cell type is available, such that a mutant cell containing a HAC can be identified by expression of the marker. A diseased cell such as a muscle cell expressing a mutant dystrophin gene in a muscular dystrophy patient is another example of a mutant cell. Thus, a normal dystrophin gene can be a selectable marker, which, when introduced using a MAC into the mutant muscle cell, results in the previously mutant muscle cells attaining a normal muscle cell phenotype. A selectable marker can allow a cell to survive in the presence of a drug that otherwise would kill the cell. Such selectable markers, include, for example, positive selectable markers that confer resistance to neomycin (geneticin; G418), puromycin or hygromycin B. In - 27 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) comparison, a selectable marker such as the Herpes simplex virus thymidine kinase (HSV-tk) is useful for either positive selection, for example, in a cell that is deficient in thymidine kinase activity, or negative selection, whereby cells expressing HSV-tk are killed by exposure to gancyclovir. Such selectable markers are useful because they confer an identifiable phenotype on an otherwise normal cell and, therefore, do not require the availability of a mutant cell. These and other selectable markers are well known in the art and commercially available (see, for example, Sambrook et al., Molecular Cloning: A laboratory manual (Cold Spring Harbor Laboratory Press 1989), which is incorporated herein by reference; see pages 16.9-16.15). In addition, a selectable marker can be a product that allows a cell containing the HAC to be identified visually among a population of cells, some of which do not contain the selectable marker. Examples of such selectable markers include the green fluorescent protein (GFP), which can be visualized by its fluorescence; the luciferase gene, which, when exposed to its substrate luciferin, can be visualized by its luminescence; and β-galactosidase (β-gal), which, when contacted with its substrate, produces a characteristic color. Such selectable markers are well known in the art and the nucleic acid sequences encoding these markers are commercially available (see Sambrook et al., supra, 1989). Methods In another aspect, the present disclosure provides a method for preparing a human artificial chromosome (HAC) lacking repetitive centromere DNA, wherein the HAC comprises one or more genomic loci comprising a coding sequence and a non-coding sequence, and no more than one CENP-A locus, wherein the HAC replicates and segregates in a host cell independently of a natural chromosome of the host cell, the method comprising performing transformation-associated recombination (TAR) comprising a first vector comprising a region for acquiring CENP-A chromatin and a second vector comprising one or more genomic loci. In certain embodiments, the method further comprises seeding a CENP-A nucleosome on the region for acquiring CENP-A chromatin. In certain embodiments, the seeding comprises contacting the region for acquiring CENP-A chromatin with a Holliday junction recognition protein (HJURP). In certain embodiments, the first vector or second vector comprise DNA suitable for expression of the - 28 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) HJURP. In certain embodiments, the first vector or second vector comprise DNA suitable for inducible expression of the HJURP. In certain embodiments, the seeding occurs in a mammalian cell or mammalian-yeast hybrid. In certain embodiments, the mammalian cell or mammalian-yeast hybrid comprises DNA suitable for expression of a Holliday junction recognition protein (HJURP). In certain embodiments, the mammalian cell or mammalian-yeast hybrid comprises DNA suitable for inducible expression of a Holliday junction recognition protein (HJURP). In certain embodiments, the method further comprises performing spheroplast fusion between a yeast cell comprising the one or more genomic loci, CENP-A, and a mammalian recipient cell. In another aspect, the present disclosure provides a method of preparing a human artificial chromosome (HAC) vector, the method comprising: (a) fusing a yeast cell comprising the human artificial chromosome (HAC) template of the present disclosure with a recipient mammalian cell to provide a hybrid cell, wherein the recipient mammalian cell comprises DNA suitable for inducible expression of a fusion protein comprising at a lac repressor (LacI) and a Holliday junction recognition protein (HJURP); and (b) including expression of the fusion protein. In certain embodiments, the fusion comprises spheroplast fusion. In certain embodiments, the recipient mammalian cell is selected from the group consisting of HT1080 and U2OS. In certain embodiments, the recipient mammalian cell comprises a doxycycline-inducible expression vector. In certain embodiments, the fusion protein further comprises mCherry. In another aspect, the present disclosure provides a method of preparing a human artificial chromosome (HAC) vector, the method comprising: (a) fusing a yeast cell comprising the human artificial chromosome (HAC) template of the present disclosure with a recipient mammalian cell to provide a hybrid cell, wherein the HAC template comprises DNA suitable for inducible expression of a fusion protein comprising at a lac repressor (LacI) and a Holliday junction recognition protein (HJURP); and - 29 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) (b) including expression of the fusion protein. In certain embodiments, the fusion comprises spheroplast fusion. In certain embodiments, the recipient mammalian cell is selected from the group consisting of HT1080 and U2OS. In certain embodiments, the recipient mammalian cell comprises a doxycycline-inducible expression vector. In certain embodiments, the fusion protein further comprises mCherry. Cell Therapy In another aspect, the present disclosure relates to a human artificial chromosome (HAC) vector which represents a platform for gene delivery. In certain embodiments, the platform for gene delivery comprises cell therapy. In one aspect, the present disclosure provides a cell comprising the human artificial chromosome (HAC) lacking repetitive centromere DNA, wherein the HAC comprises one or more genomic loci comprising a coding sequence and a non-coding sequence, wherein the one or more genomic loci comprise no more than one focus of CENP-A chromatin, wherein the HAC replicates and segregates in a host cell independently of a natural chromosome of the host cell. In another aspect, the present disclosure provides a cell comprising the human artificial chromosome (HAC) vector of the present disclosure. In certain embodiments, the foreign DNA in the HAC vector encodes at least one gene product suitable for the treatment, prevention, and / or amelioration of a disease or condition, or for rejuvenation of an immune system. In one aspect, the present disclosure provides a method for treating, preventing, and / or ameliorating a disease or condition, or for rejuvenation of an immune system, in a subject in need thereof, the method comprising administering to the subject the human artificial chromosome (HAC) of the present disclosure or the cell of the present disclosure. In another aspect, the present disclosure provides a method of treating, preventing, and / or ameliorating a disease or condition, or for rejuvenation of an immune system, in a subject in need thereof, the method comprising administering to the subject the human artificial chromosome (HAC) vector of the present disclosure or the cell of the present disclosure, wherein the foreign DNA sequence encodes a gene product useful for the treatment, prevention, and / or amelioration of the disease or condition, or for rejuvenation of an immune system. - 30 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) In some embodiments, the disease or condition comprises a degenerative disease or condition. In another embodiment, the disease or condition comprises joint pain, osteoarthritis, cancer, or a metabolic disease (e.g., diabetes). In other embodiments, the HAC comprises a sequence encoding one or more therapeutic proteins. In one embodiment, the therapeutic protein is growth differentiation factor 11 (GDF11), hyaluronan synthase 2 (HAS2), a chimeric antigen receptor (CAR), insulin, or glucagon. EXAMPLES Various embodiments of the present application can be better understood by reference to the following Examples which are offered by way of illustration. The scope of the present application is not limited to the Examples given herein. Materials and Methods Cell lines The H. sapiens fibrosarcoma-derived HT1080Dox-inducible mCherry-LacI-HJURPcell line was cultured in DMEM with 4.5 g / L D-Glucose and L-Glutamine (Gibco) supplemented with 10% FBS, 100 U / mL penicillin, and 100 µg / ml streptomycin at 37 °C in a humidified incubator with 5% CO2. The H. sapiens osteosarcoma-derived U2OSDox-inducible mCherry-LacI-HJURPcell line was generated via recombinase-mediated cassette exchange (RMCE) using the U2OS RMCE system. This system allowed us to insert the dox-inducible mCherry-LacI-HJURP transgene cassette at a single genomic locus. Briefly, a monoclonal U2OS acceptor cell line with loxP and lox2272 recombination sites at a single chromosomal locus was co-transfected with a donor plasmid containing an mCherry-LacI-HJURP gene under the control of a tetracycline-responsive element (TRE) (all flanked by loxP and lox2272 sites) and a second plasmid expressing Cre recombinase (pEM784). The cells were co-transfected at a 100:1 ratio (990 ng mCherry-LacI-HJURP donor plasmid and 10 ng Cre recombinase plasmid) using FuGENE 6 (Promega).2 days after transfection, 2 µg / mL puromycin was added to the growth medium for selection of the stable cell line.2 µg / mL doxycycline was added to the growth medium for 48 h to induce expression of mCherry-LacI-HJURP from the TRE promoter. - 31 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) Yeast artificial chromosomes (YAC) construction The HAC forming yeast construct, YAC Mm-4q21LacO, was developed by combining the YAC containing M. mycoides (Mm) genomic DNA (JCVI-syn3B) and the BAC 4q21BACLacOvia transformation associated recombination (TAR) cloning. The YAC was first linearized via CRISPR-Cas9. The 4q21BAClacOwas broken into two fragments via restriction digest with Nru1 and Mre1. The two 4q21BAClacOfragments along with four linker fragments were delivered to yeast cells containing the linearized YAC Mm. Because these components were all designed to have homology with each other, and yeast are highly efficient at homologous recombination, the various components were combined into one larger construct (FIGs.1A-1C). The success of the TAR cloning was confirmed via 4 PCR reactions on the expected construct (FIG.1C). This was achieved by first transforming yeast cells containing M. mycoides genomic DNA with the plasmid, pDB18-cas9-CRISPR which contains an expression cassette for guide RNAs to cut the yeast construct and Cas9. Yeast were grown in 30 mL SD-HIS overnight at 30 ℃. Yeast cells were spun down at 3000 rpm for 3 min in a Eppendorf 5810R Centrifuge. Cells were resuspended to an OD600 of 0.4 in YPG. Yeast cells were grown for 6 hours to an OD of 1. Then, 1.5 mL of cells were removed from culture and spun down at 14,000 rpm for 15 s with a Sorval Legend Micro 21 centrifuge. The supernatant was removed and resuspended in 1 mL 0.1 M Li-actetate. Cells were spun again at 14,000 rpm for 15 s before resuspending in 1 mL 0.1 M Li-acetate. Cells were incubated at 30 ℃ for 30 min. Cells were spun down at 5,000 rpm for 3 min. Cells were resuspended in 50 µL 0.1 M Liac / 1XTE, and add 5 µL denaturated carrier DNA (10 ug / ml sheared salmon sperm DNA) and 10 µl DNA insert mix comprised of digested 4q21BACLacOas well as 4 linkers fragments (FIGs.1A-1C). With mixing between each addition, 500 µL of 40% PEG 4000 and 56 µL of DMSO were added to the solution. The solution was incubated for 30 min at 30 ℃ and then 25 min at 42 ℃. The solution was spun at 5,000 rpm for 3 min before resuspending in 100 µL water and plating on SD-HIS-URA plates. Junction PCR to assess YAC Genomic DNA was prepared as described by first growing yeast overnight in a 5 ml culture to an OD600> 0.4. Then, 200 µl of yeast was centrifuged at 2000 × g for 3 min at 4 °C. Yeast was resuspended in 100 µl 200 mM LiOAc with 1% SDS and incubated for 5 min at 70 °C. Yeast DNA was first extracted with phenol-chloroform-isoamyl alcohol (25:24:1, - 32 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) ThermoFisher) before precipitating with isopropanol and resuspending in elution buffer (EB; Qiagen). YAC containing yeast were assessed by PCR using Q5® Hot Start High-Fidelity 2X Master Mix (New England Biolabs: M0494S). The primers sets used were: (1: Fwd: 5’- GTACCACCGCAACTTTCTTG-3’, (SEQ ID NO:2); Rev: 5’- CGGCGCAGTTTCTGAGAAG- 3’, (SEQ ID NO:3); 2: Fwd: 5’-TATTGGTGAACCAGTGGG-3’, (SEQ ID NO:4); Rev: 5’- CCTTGTTCAACACGTAATACTG-3’, (SEQ ID NO:5); 3: Fwd: 5’- CCGTAATATCCAGCTGAACG-3’, (SEQ ID NO:6); Rev: 5’- CAGCCAAGATATCAGCATCA-3’) (SEQ ID NO:7). Thirty-five colonies were assessed and nine were clearly positive for all three PCR reactions. Sequencing to assess the YAC For short-read sequencing, 3 µg yeast genomic DNA was digested with NEBNext dsDNA Fragmentase (New England Biolabs: M0348S) in Fragmentase Reaction Buffer v2 at 30 °C for 30 min before stopping the reaction with 5 µl .5 M EDTA. Sequencing libraries were generated and barcoded for multiplexing according to Illumina recommendations with minor modifications. Briefly, 10 ng DNA was end-repaired and A-tailed. Illumina TruSeq adaptors were ligated, libraries were size-selected to exclude polynucleosomes, and the libraries were PCR-amplified using KAPA DNA polymerase (Sigma-Aldrich). All steps in library preparation were carried out using New England BioLabs enzymes except as noted. Resulting libraries were submitted for 75-bp, single-end Illumina sequencing on a NextSeq 500 instrument. For Oxford Nanopore Technologies (ONT) long-read sequencing of yeast harboring YAC-Mm-4q21LacO, genomic DNA was first incubated in 25 µg / ml RNase for 1 h at 37 °C and then extracted as before phenol-chloroform-isoamyl alcohol before precipitating with isopropanol. Once the DNA was fully resuspended in EB the following day, DNA was sheared with a g-tube (Covaris) we prepared the DNA for ONT long-read sequencing using the ONT ligation sequencing kit (ONT; # SQK-LSK112), following the manufacturer’s instructions. The library was loaded onto a primed FLO-MIN106 R9.4.1 flow cell for sequencing on the MinION. All ONT data was base-called with Guppy 3.6.0 (GitHub) with the HAC model. To generate the sequence of the YAC, our expected input sequence, short (because of the high read accuracy) and long (to identify any major sequence rearrangements) read sequencing data was input into the EPI2ME pipeline wf-bacterial-genomes v0.2.12 (GitHub). The draft - 33 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) assembly output was used as a template for two kinds of manual revisions. First, in several places long reads spanned a gap with no coverage, the regions with no coverage were deleted to allow continuous coverage of those long reads. Second, in two locations, there were insertions not represented by the existing sequence map. Thus, reads with alignment to those regions were identified and the sequence from those reads not on the existing map was added to the assembly. Alignments were performed via the EPI2ME pipeline wf-alignment v0.3.3 (GitHub). Spheroplast fusions Yeast containing the YAC construct Mm-4q21LacOwere grown overnight to saturation in a 5 mL culture of SD-URA. This culture was diluted to 50 mL in SD-URA and grown for 7-8 hours at 30 ℃ to an OD600 of 0.8-1.0. Yeast were centrifuged at 3,000 rpm for 3 min and resuspended in 20 mL 1 M sorbitol and incubated at 4 ℃ overnight (<18 hours). Yeast cells were spun down at 3,000 rpm for 3 min and resuspended in 20 ml SPEM (1M sorbitol, 10 mM EDTA, 10 mM sodium phosphate at pH 7.4).40 µL of BME and 60 µL of zymolase (stock solution of 200 mg Zymolase 20-T was resuspended in 9 mL H2O, 1 mL 1 M Tris pH 7.5, 10 mL 50% glycerol and stored at -20 ℃) were added to the yeast solution. Yeast were incubated for 1 hour at 37 ℃ to digest the cell wall. The success of spheroplasting was assessed by measuring the OD600 of solution diluted 1:10 in 1 M sorbitol and 1:10 in 2% SDS. The 37 ℃ incubation was continued until the OD600ratio was >10.30 ml of 1 M sorbitol at 4 ℃ was added before spinning at 1,800 rpm for 8 min at 4 ℃. The pellet was resuspended in 20 mL 1 M sorbitol before adding an additional 30 mL of 1 M sorbitol. The solution was spun at 1,800 rpm for 8 min at 4 ℃. The pellet was resuspended in 1 mL of STC (1 M sorbitol, 10 mM CaCl2, 10 mM tris pH 7.5) and incubated at RT for 10-60 min. Tissue culture cells were processed in parallel to yeast. The day of fusion, 10 µL of 50 mg / ml STLC was added to 70-80% confluent plate of HT1080 or U2OS cells for 6 hours. Cells were trypsinized and neutralized with DMEM before counting on a hemacytometer and spinning at 1,500 rpm for 5 min at RT. Cells were resuspended in PBS to a concentration of 6 x 105cells / mL. The concentration of yeast cells was determined by assuming 2 x 107cells per OD per ml. 3 x 105mammalian cells and 9 x 107yeast cells were mixed in an Eppendorf tube and incubated - 34 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) for 5 min at RT. The mixture was spun at 4,000 rpm for 30 s on a Sorval Legend Micro 21 centrifuge. The pellet was resuspended in 45% PEG, 10% DMSO in 75 mM HEPES and incubated for 5 min at RT. The reaction was quenched by adding 1 mL of DMEM to solution before spinning at 4,000 rpm for 30 s. The mixture was resuspended in 1 mL of DMEM before adding the mixture to a 6- well plate containing 2 mL of DMEM. After 3-4 h and cells annealed to the plate, media was replaced with fresh media containing 2 µg / ml doxycycline. Media was replaced again (with 2 µg / ml doxycycline) the following morning. HAC formation assay After fusion, cells were incubated in DMEM with 2 µg / ml dox for 48 h. Next, cells were trypsinized and moved to a 10 cm plate and cultured in DMEM with 333 µg / ml G418 for 1 week and 1 day. Cells were then moved to a lower concentration of G418 (150 µg / ml) and, after three days, were assessed by IF-FISH, frozen down, or isolated into single clones. Isolating clones Polyclonal HAC lines were first trypsinized before quenching with DMEM. Cells were spun at 1,500 rpm for 5 min before being washed once with PBS. Cells were counted by hemacytometer and spun at 1,000 rpm for 3 min before resuspending in 10 mL PBS with 1 mM EDTA twice. Cells were spun again at 1,000 rpm for 3 min before resuspending in PBS + 1mM EDTA + 1% BSA to a final concentration of 106cells / ml before being transferred to a 5 mL sterile polystyrene tube. Single cells were sorted in wells of a 96 well plate using a FacsJAZZ sorter. Cells were cultured for ~2-3 weeks in 50% DMEM and 50% conditioned media. Conditioned media was made by culturing HT1080 or U2OS cells overnight, collecting media and filtering with a .22 µm filter. After colonies were visible, cells were scaled up to a 24-well, 6-well and then 10 cm plate while culturing in DMEM with 150 µg / ml G418. Clones were checked for HACs via IF-FISH on metaphase spreads. IF-FISH on metaphase spreads or isolated HACs IF-FISH was performed according to methods known to those of ordinary skill in the art, with some modifications. HT1080 cells were treated with 50 µM STLC (Sigma-Aldrich) for 2-4 - 35 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) h to arrest cells during mitosis. Mitotic cells were blown off using a transfer pipette and swollen in a hypotonic buffer consisting of a 1:1:1 ratio of 75 mM KCl, 0.8% sodium citrate, and 3 mM CaCl2and 1.5 mM MgCl2for 15 min. Alternatively, in the case of HACs isolated from sucrose gradient (see below) 50 µL of HAC solution was diluted 1:10 in dH2O.3x104cells (or 500 µL diluted HAC solution for isolated HACs) were cytospun in an EZ Single Cytofunnel in a Shandon Cytospin 4 onto an ethanol- washed positively charged glass slide and allowed to adhere for 1 min before permeabilizing with KCM buffer for 15 min. Cells were blocked for 20 min in IF block buffer (2% FBS, 2% BSA, 0.1% Tween-20, and 0.02% NaN3) before incubating for 45 min at RT (3 h for IF on isolated HACs) with a monoclonal anti-CENP-A antibody (Enzo; ADI-KAM-CC006-E) diluted 1:1000 in IF block buffer. Slides were washed 3 x 5 min in KCM. Slides were incubated for 25 min at RT with Cy3 conjugated to donkey anti-mouse diluted 1:200. Slides were washed 3x in KCM for 5 min at RT. Slides were fixed in 4% formaldehyde in PBS, before washing 3x in dH2O for 1 min each. Slides were incubated with 5 µg / ml RNAse A in 2x SSC at 37 C for 5 min. Cells were subjected to an ethanol series to dehydrate the cells and then denatured in 70% formamide / 2x SSC at 77 ℃ for 2.5 min. Cells were dehydrated with an ethanol series. Biotinylated DNA probe was generated using purified mycoplasma DNA with a Nick Translation Kit (Roche; 10976776001) according to the manufacturer’s instructions, purified with a G-50 spin column (Illustra), and ethanol-precipitated with salmon sperm DNA and Cot-1 DNA. Precipitated BACLacO DNA or LacO plasmid was suspended in 50% formamide / 10% dextran sulfate in 2x SSC and denatured at 77 ℃ for 5-10 min before being placed at 37 ℃ for at least 20 min.300 ng DNA probe was incubated with the cells on a glass slide at 37 ℃ overnight in a dark, humidified chamber. The next day, slides were washed 2x with 50% formamide in 2x SSC for 5 min at 37 ℃ (45 ℃ for repetitive LacO FISH probe). Next, slides were washed 2x with 2x SSC for 5 min at 37 ℃ (45 C and 0.1x SSC for repetitive lacO FISH probe). Slides were blocked with 2.5% milk in 4x SSC with 0.1 Tween 20 for 10 min. Cells were incubated with NeutrAvidin-FITC (ThermoFisher Scientific; 31006) diluted to 25 µg / mL in with 2.5% milk in 4x SSC with 0.1 Tween 20 for 10 min for 1 h at 37 ℃ in a dark, humidified chamber. Cells were washed 3x with 4x SSC and 0.1% Tween 20 at 45 C, DAPI-stained, and mounted on a glass coverslip with Vectashield (Vector Labs). - 36 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) Slides were imaged on an inverted fluorescence microscope (Leica DMI6000B) equipped with a charge-coupled device camera (Hamamatsu Photonics ORCA AG) and a 100x 1.4 NA objective lens. Characterizing HACs A “small HAC” designation was given if the cell contained a chromosome in which the FISH signal colocalized with CENP-A signal, was not overlapping an endogenous centromere, and the maximum diameter was <1.0 µm. A “large HAC” designation was given if the cell contained a chromosome in which the FISH signal colocalized with CENP-A signal, was not overlapping an endogenous centromere, and the maximum diameter was >1.0 µm. An “integration” designation was given if the cell contained a chromosome in which FISH probe signal localized to the DAPI-stainable region on the chromosome but did not colocalize with CENP-A signal; and a “no signal” designation was given if the cell did not contain a FISH probe signal on any DAPI-stainable region or colocalized with CENP-A signal. For polyclonal HAC lines, 50 spread were counted for each experimental condition and each HAC assay was performed in triplicate. The fraction of HACs with each designation was determined by dividing by 50. For isolated clones, 20 spreads were imaged and a clone was considered a HAC line if >20% of spreads contained a “small HAC” and no integrations or large HACs were present. The fraction of HACs in the isolated clone was determined by dividing the total # of “small HACs” by 20. eGFP-LacI lentivirus production HA-LacI or EGFP-LacI lentivirus was produced by co-transfecting the HA-LacI or EGFP-LacI lentiviral plasmid and two packaging plasmids, pMD2.G and psPax2 (Addgene plasmids #12259 and #12260, respectively), into 293GP cells (Morgenstern and Land, 1990) and harvesting the media 48 h later. Specifically, a 10 cm plate of 50%–80% confluent 293GP cells was transfected with 6 mg of DNA (3 mg of the HA-LacI lentiviral vector, 750 ng pMD2.G, and 2.25 mg psPax2) and 18 mL of FuGENE 6 (Promega). The culture medium was changed 6-24 h later.48 h post- transfection, the culture medium was harvested, filtered through a 0.45 mm filter, and stored at 80 ℃. - 37 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) IF on STLC synchronized cells to assess inner centromere HAC containing cells were plated in a 6-cm plate (in the presence of 150 µg / mL G418-S) and allowed to adhere to the bottom of the plate. The next day (when cells were 20%–30% confluent), the culture medium was replaced with fresh medium containing 500 µL of eGFP-LacI lentiviral supernatant and 18 µg polybrene (Specialty Media, TR-1003-G).24 h later, the culture medium was changed to remove the lentiviral particles and polybrene. 48 h post-transduction cells were seeded on an 18x18 mm2polystyrene coated coverslip the night before IF. Coverslips were transferred to a 6-well plate containing preheated PBS. PBS was removed via aspiration and cells were fixed in 1 ml of 4% formaldehyde in PIPES with 1% Triton- X-100 was added to each well and incubated for 20 min at 37 ℃. Formaldehyde solution was removed and fixing quenched with 2 mL 100 mM Tris pH 7.5 for 5 mins. Slides were washed 3x in 2 mL PBS + 0.1% Tween for 5 mins. Slides were blocked in IF Block (2% FBS, 2% BSA, 0.1% Tween-20, and 0.02% NaN3) for 20 min at RT. Slides were then incubated for 45 min at RT in a human ACA affinity purified antibody diluted 1:1,000 (in-house), mouse Aim-1 antibody diluted 1:1,000 (BD Transduction Laboratories; 611082, 611083), and rabbit anti-GFP antibody (in-house) diluted 1:100,000 in IF Block. Slides were washed 3x in 2 mL PBS + 0.1% Tween for 5 mins. Slides were then incubated for 25 min at RT in IF Block with Cy5 conjugated to donkey anti-human diluted 1:200, Cy3 conjugated to donkey anti-mouse, and FITC conjugated to goat anti-rabbit. Slides were washed in 2 mL PBS + 0.1% Tween for 5 mins before incubating in DAPI diluted 1:10,000 in PBS + 0.1% Tween-20 for 10 min. Coverslips were washed in PBS + 0.1% Tween-20, PBS, and then dH2O before mounting coverslips on slides with vectashield. Slides were imaged on an inverted fluorescence microscope (Leica DMI6000B) equipped with a charge-coupled device camera (Hamamatsu Photonics ORCA AG) and a 40x 1.4 NA objective lens. HACs were identified via the presence of GFP signal. Each HAC was determined to be Aurora B positive if Aurora B signal was at least 50% above background. The total fraction of Aurora B positive HACs was tallied across three independent experiments. Immunoblotting - 38 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) Samples prepared from whole cell lysates were separated by SDS-PAGE and then transferred to nitrocellulose membrane. Blots were probed using the affinity purified human anti- centromere antibody at 0.74 µg / ml and horseradish peroxidase-conjugated donkey anti-human IgG (1:10,000, Jackson ImmunoResearch Laboratories #709-035-149). Antibodies were detected by enhanced chemiluminescence (ThermoFisher Scientific). HAC retention assay Four isolated HAC clones were cultured in the absence of G418-S selection for 30 days in triplicate. IF-FISH was performed at Day 0 and Day 30, and at least 20 cells were assessed for the presence of a HAC in each cell line at both time points. A daily HAC loss rate was determined using the following equation: N30 = N0 (1-R)30, where R is the daily HAC loss rate and N0 and N30 are the number of metaphase chromosome spreads containing a HAC at Day 0 and Day 30, respectively. Interphase IF-FISH Clone 8 cells were washed in PBS and incubated in trypsin to resuspend. The suspension was quenched in DMEM, centrifuged, and then resuspended to a 2.5 × 107cells / ml concentration.100 µl of the cell suspension was pipetted into the center of a positively charged slide bordered by a hydrophobic barrier using a PAP pen. Cells were allowed to adhere for two hours before washing twice with PBS and fixing with 4% formaldehyde for 10 minutes at room temperature. Fixation was quenched with 100 mM Tris-HCl, pH 7.5 and then cells were permeabilized with KCM buffer (10 mM Tris-HCl, pH 7.7, 120 mM KCl, 20mM NaCl, 0.1% Triton X-100). Cells were washed in KCM 3x prior to incubating cells in IF block (2% FBS, 2% BSA, 0.1% Tween-20, 0.02% NaN3 in 1X PBS). From here, CENP-A IF-M. mycoides FISH was conducted as described, above, for IF-FISH on metaphase spreads. Table 1. Summary of exemplary HAC clones of the present disclosure Clone % of cells with HACs Identifier - 39 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) 5 0.60 yBB6 HAC 1-23 6 0.65 yBB6 HAC 4-1-1 8 15-cm plates of HAC cells were cultured to a confluence of 80-95%. Cells were spun at 1,500 rpm for 5 min at 4 ℃ and resuspended in 30 mL of PBS. Cells were counted via hemacytometer. Cells were spun at 1,500 rpm for 5 min at 4 ℃. Keeping cells on ice, the cell pellet was resuspended in 0.32 M sucrose in 60 mM KCl, 15 mM NaCl, 5 mM MgCl2, .1 mM EGTA, 0.5 mM DTT, 0.1 mM PMSF, 1 mM leuptatin / pepstatin, 1 mM aprotinin, and 15 mM Tris pH 7.5.2 ml of 0.32 M sucrose in 60 mM KCl, 15 mM NaCl, 5 mM MgCl2, .1 mM EGTA, 0.5 mM DTT, 0.1 mM PMSF, 1 mM leupeptin / pepstatin, 1 mM aprotinin, and 15 mM Tris pH 7.5 with 0.1% IGEPAL were added to 2 mL of cells and incubated for < 10 min. The mixture was added onto a sarstedt tube containing 8 mL of 1.2 M sucrose in 60 mM KCl, 15 mM NaCl, 5 mM MgCl2, 0.1 mM EGTA, 0.5 mM DTT, 0.1 mM PMSF, 1 mM leuptatin / pepstatin, 1 mM aprotinin, and 15 mM Tris pH 7.5. The mixture was added slowly to avoid mixing the two layers of differing sucrose concentration. The sucrose gradient was spun at 10,000 g, 20 mins, 4 °C at acceleration 9 and deceleration 5 with an SS-34 rotor in a Sorvall centrifuge. Individual 1 mL were collected for qPCR analysis and the top ~2.5 mL of solution (with care to avoid collecting cell debris) were collected for lacO FISH experiments. qPCR of sucrose gradient enriched HACs DNA collected from sucrose gradient was first Phenol-Chloroform-Isoamyl alcohol extracted before precipitating with isopropanol. DNA concentrations were determined via nanodropping. qPCR was performed in triplicate with 10 ng of initial DNA used in each reaction. qPCR amplification was detected using a 2x SYBR green master mix. Two primer sets were used, one with amplification of the CENP-A gene (present on endogenous chromosome) and another with amplification of the NeoR gene (present on the HAC). HAC enrichment was determined by the following calculation: fold enrichment = 1.8^([Ct sucrose fraction CENP-A gene – Ct sucrose fraction NeoR gene] – [Ct genomic DNA CENP-A gene – Ct genomic DNA - 40 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) NeoR gene]. IF-FISH on HACs isolated via sucrose gradient HACs collected from the top of a sucrose gradient were cytospun onto slides and processed for IF- FISH as described above with some modifications. Before cytospinning, the HAC solution was diluted in H2O for 15 min. Next, during IF, slides were incubated at RT with CENP-A antibody for 2.5 h. HACs were identified on the slide via colocalization of DAPI (with size <2.5 µm and > 0.5 µm), CENP-A signal and FISH signal (lacO). The number of foci containing CENP-A signal or LacO signal were counted from two separate experiments. Quantification of IF-FISH on HACs isolated via sucrose gradient Three-dimensional Z-stacks were processed using a maximum intensity projection algorithm into a two-dimensional image containing pixels of highest intensity from every slice of the Z-stack. Distances were measured between CENP-A and LacO from the pixels that had the maximum quantified intensity for each respective fluorescent signal (Mean = 0.13 μm, SD = 0.07 μm, N = 48). A one sample t-test using a hypothetical mean of 0, denoting that CENP-A and LacO are not distinctly localized, was performed. Further enrichment of HACs for sequencing and H3K9me3 IF-FISH The top 2.5 ml from the initial sucrose gradient step, described above, was collected using a cut pipette tip. This fraction was then loaded onto a second sucrose gradient comprised of 22% and 30% v / v sucrose both in 60 mM KCl, 15 mM NaCl, 5 mM MgCl2, 0.1 mM EGTA, 0.5 mM DTT, 0.1 mM PMSF, 1 mM leuptatin / pepstatin, 1 mM aprotinin, and 15 mM Tris (pH 7.5). This solution was centrifugated at 20,000 × g for 20 min at 4 °C using an SW 60 Ti Swinging- Bucket Rotor in a Beckman Coulter Ultracentrifuge. At the 22-30% interface, 500 µL of solution was collected using a cut pipette tip. For sequencing, a phenol-chloroform DNA extraction was performed on the collected solution. IF-FISH was performed, as above, but here α-H3K9me3 (1:500; Abcam; ab8898) was used followed by a Cy5 donkey anti-rabbit secondary diluted 1:200 (Jackson ImmunoResearch: 711-175-152). Southern blots - 41 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) Genomic DNA from the indicated cell lines (the multimerized HAC line used was Clone 11 from and was diluted 20-fold in HT1080 HiLo cells) was prepared in agarose plugs by resuspending 5 × 106cells / ml in 0.8% agarose and digested overnight with FseI (NEB; R0588L) at 37oC. Digested DNA was separated via CHEF electrophoresis (Bio-Rad, CHEF DR II System) at 3 V / Cm, 250 to 900 s, for 50 h. The blot was transferred to a membrane (Amersham Hybond-N+) and blot-hybridized with a 100 bp probe that binds to the LacO sequence (5’- TTGTTATCCGCTCACAATTCCACATGTGGCCACAAATTGTTATCCGCTCACAATTCCA CATGTGGCCACAAATTGTTATCCGCTCACAATTCCACATGTG-3’) (SEQ ID NO:8). The LacO-specific probe was end labeled with32P-γ-ATP for 1 h at 37 °C before cleaning with illustra ProbeQuant G-50 micro column (GE Healthcare; 28-9034-08). The blot was incubated for 2 h at 42 °C in hybridization buffer (ULTRAhyb™ Ultrasensitive Hybridization Buffer [Invitrogen; AM8669]). The probe was added to hybridization buffer and hybridized to the blot overnight at 38 °C. The blot was washed twice with 2x SSC with 0.5% SDS for 30 min at 42 °C. Finally, the blot was exposed to a phosphorimager screen for 2 weeks before imaging with an Amersham Typhoon. FISH on stretched chromatin fibers Extended chromatin fibers from human cells were prepared and FISH was performed as described with some modifications. The modified steps include the following: 5 × 104of HAC- containing cells were pelleted by centrifugation at 1000 × g for 5 min at RT. The cell pellet was resuspended in 500 μl of hypotonic buffer (75 mM KCl) and incubated for 10 min at RT. Slides were then cytospun for 4 min at 800 rpm on high acceleration in a Shandon Cytospin 4 onto a poly-lysine coated glass slide. Slides were transferred quickly into a falcon tube containing freshly prepared salt-detergent lysis (SDL) buffer composed of 25 mM Tris-HCl (pH 9.5), 500 mM NaCl, 1 mM PMSF, and 1% Triton X-100. After 20 min of incubation at RT, slides were washed for 15 min in PBS supplemented with 0.1% Triton X-100 and again in SDL buffer for 15 min before fixation with 3.7% formaldehyde. For experiments with mitotic enrichment for chromatin fiber stretching, colcemid was added to cell cultures at a final concentration of 0.1 µg / ml and incubated at 37 °C in the presence of 5% CO2for 3-4 h. Growth flasks were then gently tapped with the palm of the hand, dislodging mitotic cells from the surface. Mitotic cells were harvested and transferred into a 15 ml falcon tube and centrifuged at 1500 rpm for 5 min at - 42 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) RT. The pellet was resuspended in 0.5 ml PBS and cells were counted. An aliquot of cell suspension of concentration 1 × 105cells / ml was centrifuged at 1500 rpm for 5 min at RT. The pellet was resuspended in 1 ml of hypotonic buffer and incubated at RT for 15 min. An aliquot of 500 µl of cell suspension was loaded into cytospin funnel with poly-lysine coated slide and centrifuged at 1500 rpm for 5 min with cytospin set to high acceleration. One slide was carried through the fiber preparation protocol and the other slide proceeded through the mitotic spread protocol described above as a control slide to confirm successful mitotic chromosome enrichment. Chromatin fibers from budding yeast were made from spheroplasts using an established protocol. Here, the yeast strain harboring YAC-Mm-4q21LacOwas grown overnight in SD-URA media to ~1 × 107cells / ml. Cells were harvested at 1200 × g for 5 min at RT in a pre-weighed 50 ml falcon tube. The supernatant was decanted and the mass of the pellet was measured. The pellet was then resuspended in a mixture of 0.1 M EDTA-KOH (pH 8.0) and 10 mM DTT at 1 ml / 0.1 g of cells. The cell suspension was then incubated at 30 °C for 10 min with gentle agitation. After incubation, cells were pelleted at 800 × g for 5 min at RT. The cell pellet was carefully resuspended in a mixture of SD-URA and 1.2 M sorbitol at 1 ml / 0.1 g of cells (first resuspended with 500 µl of mixture before adjusting to the final volume). Lyticase (Sigma #L2524) and zymolyase-20T (SEIKAGAKU #120491) were added at 1000 U / ml and 300 µg / ml respectively. The cell suspension was transferred into the Erlenmeyer flask used for the overnight culture and then incubated at 30 °C for 1 h for maximum spheroplast formation of 60- 70%. Spheroplasts were centrifuged at 1000 × g for 5 min. Chromatin fiber-FISH was performed as described elsewhere herein. Short-read sequencing of cells harboring HACs Total genomic DNA or sucrose gradient fractions from the HAC enrichment procedure described above were extracted and subsequently ethanol precipitated. Library preparation was performed using Illumina 20060060 following the manufacturer instructions. Libraries were indexed during amplification using Illumina 20027213. Subsequently, libraries were loaded onto an S2 flow cell for 2x150bp sequencing with the NovaSeq 6000. Demultiplexed, adapter- removed reads were aligned against a concatenated genome consisting of T2Tv2, YBB6v3, and Saccer3 using Bowtie2 with the following arguments: -p 8 -D 20 -R 3 -N 1 -L 20 -q -t. Samtools - 43 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) was used to generate BAM files of the alignments. Reads aligning to YBB6v3 were extracted and converted into a bed coverage file for view in the UCSC genome browser. In order to view the alignment track, the YBB6v3 sequence was uploaded as a custom hub. Snipgenie v0.6.0 was used to assess the sequence integrity of covered regions and inspection of potential variants. The following sequences were extracted from YBB6_manual_revisions_v3: 378324-380510, 555068-558944, and 751339-757911) into a single reference FASTA. Said reference was used for aligning enriched library reads to assess for SNP and indel variants. Example 1: Discovery of “filler DNA” suitable for preparation of human artificial chromosomes (HACs) In one aspect, the present invention relates to the discovery of the properties of an inert megabase DNA sequence (e.g., 0.5-10.0 Mb) which enabled the preparation of human artificial chromosomes (HACs). In certain embodiments, a construct may be of a suitable size to prevent multimerization and further permit visualization by Southern blotting and / or fluorescence in situ hybridization (FISH) experiments. In certain embodiments, constructs comprising a synthetic centromere, lacI DNA repeats, a CENP-A gene, one or more antibiotic resistance genes, and inert “filler” DNA, the presence of which was intended to increase the size of the HAC rather than encode proteins were prepared. A library of 18 yeast centromeric plasmids (YCPs) containing complete circular bacterial genomes plus approximately 3 kbp of Saccharomyces cerevisiae vector sequences that enable these molecules to replicate during yeast cell division and function as yeast artificial chromosomes was prepared. However, it was discovered that, even though prokaryotic (bacterial) gene transcriptional and translational signals upstream of genes were different than transcriptional and translational signals upstream in eukaryotes, such as yeast and mammalian cells, on rare occasions bacterial genes were expressed from YCPs that were toxic to yeast cells harboring the YCP containing a bacterial genome encoding the toxic gene. However, use of genomes from bacteria which use non-standard genetic codes resulted in successful cloning attempts. Each successful attempt utilized mycoplasmas, which are a taxon of atypical bacteria known for, among other things, use of the codon UGA to encode tryptophan, which is a stop codon in the standard code. Thus, mycoplasma genes containing UGA codons - 44 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) cannot be expressed in organisms using the standard genetic code. It was reasoned that if mycoplasma genomic DNA was used as inert DNA in HACs, there was a very low chance some unexpected expression of some bacterial gene would cause problems in their experiments. Example 2: An overhauled platform for efficient HAC formation It was hypothesized that, to remain single-copy and avoid multimerization, the initial construct would need to be larger than the BAC-based HAC constructs of earlier versions. This is based on the understanding that centromeres require multiple domains with distinct functions that are spatially separated at mitosis when cohered sister chromatids align on the microtubule- based spindle. While the centromeric region harboring CENP-A nucleosomes (i.e., the region for assembling the mitotic kinetochore) typically discontinuously spans ~75-300 kb, the inner centromere is another largely heterochromatic region that regulates sister chromatid cohesion and a quality control pathway (termed “error correction”) that monitors bipolar spindle attachment. It was reasoned that BAC-based HAC constructs, which typically start in the 100-300 kb size- range, can likely only form when multimerization occurs. The larger size is presumably required to accommodate formation of both distinct chromatin domains that define a functional centromere. Conversely, it was reasoned that starting with a larger initial construct will bypass this requirement, allowing HACs to form more frequently and without multimerization. To evaluate this hypothesis, a scheme was devised that employs three recent technical advances to build and test a single-copy HAC construct (FIG.1A). First, YAC constructs are readily generated in the 0.5-2 Mb size range through transformation-associated recombination (TAR) cloning. Second, bypassing the requirement for long (>40 kb) stretches of highly repetitive centromere DNA (α-satellite) for HAC formation permits the use of non-repetitive DNA. This is critical since TAR cloning is not compatible with long repetitive sequences. Third, large YAC constructs can be efficiently delivered to mammalian cells via optimized fusion with yeast spheroplasts, potentially leading to a marked increase in independent HAC formation events relative to what has been achieved with low-efficiency transfection-based delivery of BAC-based HAC vectors in prior versions. The HAC template was constructed through TAR assembly starting with a YAC harboring 550 kb of M. mycoides genomic DNA, 4q21 BACLacO, and linkers for recombination that also include a yeast auxotrophic marker and a mammalian expression cassette for mCherry - 45 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) (FIG.1A). M. mycoides genomic DNA was chosen because it represents a heterologous DNA sequence that is known to be readily propagated in budding yeast. It serves as a non-coding sequence in the context of a eukaryotic cell and is not expected to elicit unintended or detrimental impact on HAC formation or cell function. It was also attractive because the AT richness of the M. mycoides DNA (~75%) is anticipated to support the heterochromatic nature of the inner centromere. Further, M. Mycoides DNA has already been efficiently delivered to cultured human cells, and it allows for unambiguous detection of HACs because it is comprised of unique, non-human sequence.4q21 BACLacOwas chosen because it is the only HAC construct comprised of non-repetitive DNA (182 kb of DNA from human chromosome 4 at the 4q21 locus) that has been demonstrated to form functional HACs, instead of the 40-200 kb of highly repetitive α-satellite-based BAC constructs that prior HAC studies have used. The LacO array on 4q21 BACLacOpermits subsequent targeting of mCherry-LacI-HJURP for initial seeding of CENP-A nucleosomes. This new construct is referred to herein as “YAC-Mm-4q21LacO.” For recipient cells, the HT1080Dox-inducible mCherry-LacI-HJURPline was used, in which 4q21 BACLacO-based HACs were seeded with CENP-A nucleosomes. The HT1080 background, in general, was chosen because it is the one in which HAC formation has historically been performed due to its chromatin state that is permissive to occasional centromere formation. A second recipient line, U2OSDox-inducible mCherry-LacI-HJURP, was also generated, since the U2OS background are established as an efficient recipient of YACs via spheroplast fusion. Both of the chosen recipient lines were first optimized for spheroplast fusion conditions (FIGs.2A-2B) and then subjected to HAC formation assays with YAC-Mm-4q21LacO(FIGs.2A-2B, FIGs.3A-3D, and FIG.4). Following spheroplast fusion, it was noted that, unlike prior HAC assays where only ~40 surviving colonies emerge in 2-3 weeks, a nearly confluent monolayer of G418-S-resistant cells was present after 8 days of selection. For both recipient cell types, a substantial proportion (42 + / - 9% and 46 + / - 5%) of the neomycin-resistant cells harbor HACs. Most or all of these are substantially smaller in size (<1 µm) (FIG.3B-3D) than the multimerized HACs of prior generations (~2 µm). Without induction of mCherry-LacI-HJURP, there was only a very small proportion of HACs, with the majority of cells with detectable FISH signal coming from an integration into a natural chromosome of the recipient cell (FIG.3C). These initial findings, therefore, strongly indicate exceedingly high efficiency of YAC delivery, robust HAC formation rates upon seeding CENP-A nucleosome assembly, essentially uniform avoidance of the - 46 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) stochastic and highly unlikely multimerization that has accompanied prior systems for de novo HAC formation, and no restriction to the specific cell line (HT1080) to which prior generations of HACs were confined. Example 3: YAC-Mm-4q21LacOHACs harbor multi-domain centromeres for faithful inheritance The degree to which the centromeres on the HACs could support mitotic function was next evaluated. Starting from the polyclonal population of cells that survived G418-S selection (FIG.3A-3D), 24 monoclonal isolates were screened, and 8 lines were identified harboring HACs (the other lines included 2 in which YAC-Mm-4q21LacOhad integrated into a natural chromosome and 14 with no detectable HAC). The proportion of cells in each harboring a detectable HAC was measured (FIGs.5A-5B). Sequencing analysis of four of the monoclonal isolates revealed the presence of the HAC, but no evidence of any integration of the endogenous yeast chromosomes that were also introduced during the initial spheroplast fusion step (FIGs. 6A-6E). These findings are consistent with prior studies where yeast chromosome segregation after spheroplast fusion was only observed after strong selection for rare genome integration events. Overall, the majority of cells upon isolation of a clonal line harbor HACs, matching this property of prior generations of HACs. Four of the lines (FIG.5B) were subjected to three independent HAC stability assays over a month of growth in the absence of antibiotic selection (FIG.5C). The average daily HAC loss rate of 0.011 + / - 0.006 (FIG.5C) was similarly low as prior generations of HACs. To further interrogate the initial hypothesis that a larger initial HAC construct would confer full centromere function, the mitotic recruitment of a key component of the inner centromeric error correction mechanism, the Aurora B kinase, was assessed. The inner centromere includes chromatin marked with H3T3phosand H2AT121phosmodifications for recruiting the Chromosome Passenger Complex (CPC), containing Aurora B. Inner centromeric chromatin spans several Mb on natural chromosomes. The inner centromere in metazoans is not a single thread of chromatin but rather thought to be a densely packed region that spans a linear distance of 500-1000 nm between sister centromeres. Given the high-fidelity transmission of the HACs described herein (FIG.5C), it was predicted that they are sufficiently large to generate a robust inner centromere that recruits Aurora B. In order to have the necessary dispersion of - 47 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) chromosomes in the mitotic cell for robust detection of the HAC via expression of GFP-LacI, the formation of monopolar spindles was induced, and both the kinetochore forming part of the paired sister HACs (with anti-centromere antibodies; ACA) and the inner centromere (with antibodies to Aurora B) were assessed (FIGs.5D-5E and FIGs.7A-7B). Aurora B was found in 33 / 35 HACs. Thus, these findings suggest that the increased size of YAC-Mm-4q21LacOrelative to prior HAC constructs permits a robust inner centromere without the need to undergo large- scale multimerization. This is critical since it endows YAC-Mm-4q21LacOHACs with the ability to segregate in mitosis at high fidelity alongside natural counterparts. Example 4: Single-copy HACs The small physical size of HACs formed from YAC-Mm-4q21LacO(FIGs.3A-3D) raised the possibility that they can form without any multimerization at all. To test this notion, a cytological approach was sought that reports on copy number without the deformations that happen naturally when chromosomes are attached to and stretched by the spindle or otherwise confounded by mitotic chromosome condensation. Fortuitously, it was found that nuclear envelope lysis during isolation of nuclei releases the small HACs formed with YAC-Mm- 4q21LacOthat are subsequently efficiently separated from the rest of the genome via centrifugation (FIG.8A and FIGs.9A-9D). The top gradient fractions in the 10% sucrose layer (i.e., above the visible cell debris) were harvested and the location of CENP-A and the LacO sequences determined (FIG.8B). It was anticipated a single CENP-A focus on interphase HACs, even after replication, since sister centromeres are not separated into distinct foci on natural chromosomes until just prior to nuclear envelope breakdown near mitotic onset. LacO arrays, on the other hand, when present on repeated HAC constructs do not coalesce into a single focus. HACs were readily identified in these fractions, permitting visualization of an individualized and functional metazoan chromosome in its decondensed, interphase form (FIG.8B). In the vast majority of HACs, CENP-A and LacO staining each produced a single focus (FIG.8B). No HACs with a single CENP-A focus and more than one LacO focus were observed. A small number of HACs harbored two CENP-A foci, consistent with them coming from cells that were in late G2 or early mitosis (i.e., prior to sister chromatid separation) at the time of isolation. Each of these also had precisely two LacO foci (FIG.8B). Unlike the single-copy YAC-Mm-4q21LacOHACs, prior generations of HACs are large multimers that do not separate from endogenous - 48 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) chromosomes during nuclei isolation. In these HACs, CENP-A and LacO arrays are readily visualized on mitotic HACs in chromosome spreads (FIG.8C). For the prior generation of HACs, the paired, replicated centromeres are visible as ‘double dots’ of CENP-A, whereas the LacO arrays are visible as numerous foci (FIG.8C). Taken together with the earlier detection from uniformly small-sized HACs from populations of cells with nascent YAC-Mm-4q21LacOHACs (FIGs.3B-3D), the interphase HAC experiments (FIG.8B) indicate that the new HACs are formed and maintained without multimerization. Next, the size and topology of functional YAC-Mm-4q21LacO-based HACs were assessed (FIGs.10A-10I). This is important because earlier generations of HACs typically formed in a manner accompanied by large-scale DNA sequence multimerization and even acquisition of portions (>100 kb) of host cell chromosomal DNA. YAC-Mm-4q21LacOcontains a single FseI site (FIGs.1A-1D), and it was found that two isolated HAC-containing cell lines required FseI digestion to enter a pulse-field gel (FIG.10A and FIG.11). This is consistent with well- established topological trapping of circular chromosomes prior to digestion. The mobility of the linearized HAC suggests that it has not lost or gained large fragments of DNA (FIG.10A and FIG.11). This was compared to a circular, multimerized BAC-based HAC that has one FseI site per repeating ~200 kb monomer (FIG.10A and FIG.11). Along with the cytological data indicating the HACs are single copy (FIGs.8A-8C), their behavior on pulse-field gels (FIG.10A and FIGs.7A-7B) support the notion that they function and are inherited through cell divisions with the same single-copy circular nature in which they were initially constructed in yeast. To cytologically examine YAC-Mm-4q21LacOas it exists in yeast and then after it forms a functional HAC in human cells, a well-established chromatin stretching approach was employed (FIGs.10B-10H and FIGs.12A-12D). This permits monitoring of the 182 kb region of 4q21 present on the HACs in comparison to the initial YAC construct or the endogenous locus on chromosome 4 (FIGs.10B-10H). The degree of stretching achieved is about 3-fold, making the circle fold back upon itself (FIGs.10B-10D and FIGs.12A-12D). Stretching maintains large blocks (roughly 40 kb) of chromatin linked by highly stretched regions with little or no detectable FISH signal (FIGs.10C-10D, FIG.10D, and FIGs.12A-12D). The overall length of the HAC in human cells was greater than the YAC in yeast, but smaller than native 4q21 (FIG. 10E). The number of 4q21 foci produced by stretching of the YAC in yeast or at the native locus and HAC in mammalian cells is similar (FIG.10F). We conclude that the similarity of YACs and - 49 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) HACs reflects the absence of rampant multimerization or other substantial molecular changes (FIGs.10C-10F, FIGs.1A-1D, and FIGs.6A-6E), with relatively subtle changes in length and foci number likely reflecting differences in chromatin properties between budding yeast and human cells. The number of 4q21 foci observed on the HAC varied greatly, revealing the possible existence of two HAC populations (FIG.10F). It was reasoned that the HAC would be visualized as a single chromatid early in the cell cycle (G1 and early S phase) but would be visualized as paired chromatids later in the cell cycle (late S, G2, and M). On the other hand, the native 4q21 locus would be visualized in stretching experiments as a single chromatid, even late in the cell cycle, since each natural chromosome arm location would make its own chromatin fiber. To test this notion, cells were enriched in mitosis, prior to sister chromatid separation, and it was found that the average number of 4q21 foci in the HAC increased from 4.9 (+ / - 2.9) to 8.2 (+ / - 2.1) (FIG.10H) relative to those from asynchronous cell populations (FIG.10F), whereas, the endogenous 4q21 locus has a similar number of foci after stretching in both instances (FIGs.10F and FIG.10H). It was noted that the M. mycoides chromatin appears to be relatively resistant to stretching, since there is a similar number of foci and length (FIGs.10C-10D and FIGs.12A- 12D) despite its three-fold greater length relative to 4q21 on YAC-Mm-4q21LacO. Without wishing to be bound by any theory, a possible explanation is that the AT-rich M. mycoides sequence has denser chromatin relative to the human 4q21 sequence, which could be rendered by histone modifications and / or AT-hook protein-mediated compaction. Indeed, in addition to CENP-A-containing chromatin, a portion of the HAC DNA contains chromatin harboring H3K9me3 (FIGs.9A-9D), suggesting it harbors the heterochromatin typically found in pericentromeric regions and offering a means through which differences in chromatin stretching could be achieved. HAC stretching supports the notion of a chromatinized circular topology supporting propagation and inheritance in dividing cells. Example 5: HA-LacI-HJURP is delivered to recipient mammalian cells via spheroplast fusion Bypassing stochastic multimerization of BAC / YAC precursors to generate artificial chromosomes represents a significant advance for artificial chromosome utility in basic and translational research and eventually clinical settings as well. Still, the existing approach - 50 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) necessitates retrofitting of a desired cell line with an inducible LacI-HJURP expression cassette in order to convert the described YAC-Mm-4q21LacOinto the HAC-Mm-4q21LacO. Having to introduce two desired changes in sequence is cumbersome in permissive cell types, such as immortalized cell lines, and prohibitive in primary cell types (i.e., patient or model organism derived) that have limited subculture capacity. Further, a clinical advantage to the artificial chromosome relative to other means of introducing genes that could persist with cell division (lentiviruses, transposons) is that these entities can persist without integrating into the host genome, obviating insertional mutagenesis and its tumorigenic concerns. This advantage is forfeited by utilizing insertional mutagenesis to insert LacI-HJURP into the recipient cell type. Hence, efforts were made to circumvent the initial LacI-HJURP integration step by instead exploiting the ability for the YAC-Mm-4q21LacOyeast strain to express a gene engineered into the line. In this context, integration of LacI-HJURP (fused to the HA(1x) tag for antibody-mediated detection) into a native yeast chromosome was performed such that the yeast would express HA- LacI-HJURP in culture. This HA-LacI-HJURP would then load itself onto the YAC. Following spheroplast fusion with any mammalian cell type, this pre-loaded HA-LacI-HJURP would seed CENP-A nucleosomes onto the YAC, thereby initiating the epigenetic loop for CENP-A persistence epigenetically (i.e., without having to genetically modify a recipient mammalian cell). The YAC-Mm-4q21LacO was fit to express HA-LacI-HJURP in the yeast for co-delivery with the YAC via spheroplast fusion. Integration was validated by PCR, Sanger sequencing, and ONT sequencing. Protein expression and delivery was validated by immunofluorescence. Example 6: Fusions of U2OS HiLo cells with the pTPI1>HA-LacI-HJURP; YAC-Mm- 4q21LacOresult in HAC formation Given that the centromere seed (HA-LacI-HJURP) is expressed robustly in yeast and delivered to recipient mammalian cells via spheroplast fusion, functionality was tested using the HAC formation assay. The U2OS HiLo line was selected for evaluation, as it offers an identical genetic background to the U2OS mCherry-LacI-HJURP line with the exception that it does not have the inducible mCherry-LacI-HJURP expression cassette; thus, any formed HACs could not be a consequence of leaky centromere seed expression derived from the mammalian cell. As well, the U2OS cell line is known to be compatible with HAC formation predicated on LacI- - 51 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) HJURP-mediated seeding. Finally, the line yields quality chromosome spreads for screening HAC formation events. In total, if the tool is sufficient to form HACs as it retrofitting a cell line, a preponderance of HACs in chromosome spreads relative to the negative control would be expected, which is the YAC-Mm-4q21LacOstrain, for which HACs formed would represent either assay noise or spontaneous centromere formation, which has historically been a consequence of genomic sequence acquisition. Otherwise, most of the cells that survive selection should harbor integrations. Fusion of U2OS HiLo cells with the pTPI1>HA-LacI-HJURP; YAC-Mm-4q21LacOyeast strain forms a preponderance of HACs among cells with detectable FISH signal that survive selection, which is similar to the result observed when fusing the YAC-Mm-4q21LacOyeast strain with the U2OSDox-inducible mCherry-LacI-HJURPcells followed by doxycycline induction of mCherry- LacI-HJURP expression. This suggests that the pTPI1>HA-LacI-HJURP; YAC-Mm-4q21LacOyeast strain is sufficient to form HACs in mammalian cells epigenetically (i.e., without genetically modifying the mammalian cell). Sequence Listing SEQ ID NO:1 (YAC-Mm-4q21LacO) SEQ ID NO:2 GTACCACCGCAACTTTCTTG SEQ ID NO:3 CGGCGCAGTTTCTGAGAAG SEQ ID NO:4 TATTGGTGAACCAGTGGG SEQ ID NO:5 CCTTGTTCAACACGTAATACTG SEQ ID NO:6 - 52 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) CCGTAATATCCAGCTGAACG SEQ ID NO:7 CAGCCAAGATATCAGCATCA SEQ ID NO:8 TTGTTATCCGCTCACAATTCCACATGTGGCCACAAATTGTTATCCGCTCACAATTCCACATGTG GCCACAAATTGTTATCCGCTCACAATTCCACATGTG SEQ ID NO:9 (JCVI-syn3B synthetic bacterial genome) SEQ ID NO:10 (Mycoplasma mycoides subspecies capri strain GM12) Enumerated Embodiments The following exemplary embodiments are provided, the numbering of which is not to be construed as designating levels of importance: Embodiment 1 provides a human artificial chromosome (HAC) lacking repetitive centromere DNA, wherein the HAC comprises one or more genomic loci comprising a coding sequence and a non-coding sequence, wherein the one or more genomic loci comprise no more than one focus of CENP-A nucleosomes, and wherein the HAC replicates and segregates in a host cell independently of a natural chromosome of the host cell. Embodiment 2 provides the HAC of Embodiment 1, further comprising a sequence of chromosome 4, band 21, long arm (4q21 sequence). Embodiment 3 provides the HAC of Embodiment 2, wherein the 4q21 sequence comprises the focus of CENP-A nucleosomes. Embodiment 4 provides the HAC of any one of Embodiments 1-3, wherein the coding sequence comprises one or more sequences encoding one or more polypeptides. Embodiment 5 provides the HAC of any one of Embodiments 1-4, wherein the non- coding DNA sequence comprises about 760 kilobases (kb) or more. - 53 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) Embodiment 6 provides the HAC of any one of Embodiments 1-5, wherein the non- coding DNA sequence comprises a DNA sequence that shares at least 85% sequence homology with SEQ ID NO:1. Embodiment 7 provides the HAC of any one of Embodiments 1-6, wherein the genomic loci further comprises one or more lactose operons (lacO). Embodiment 8 provides the HAC of any one of Embodiments 1-7, wherein the HAC comprises YAC Mm-4q21LacO(SEQ ID NO:9). Embodiment 9 provides the HAC of any one of Embodiments 1-8, wherein the HAC further comprises a gene encoding a Holliday Junction Recognition Protein (HJURP). Embodiment 10 provides a method for preparing the human artificial chromosome (HAC) of any one of Embodiments 1-9, the method comprising performing transformation- associated recombination (TAR) comprising a first vector comprising a region for acquiring CENP-A chromatin and a second vector comprising one or more genomic loci. Embodiment 11 provides the method of Embodiment 10, wherein the method further comprises seeding a CENP-A nucleosome on the region for acquiring CENP-A chromatin. Embodiment 12 provides the method of Embodiment 11, wherein the seeding comprises contacting the CENP-A locus with a Holliday junction recognition protein (HJURP). Embodiment 13 provides the method of Embodiment 12, wherein the first vector or second vector comprise DNA suitable for inducible expression of the HJURP. Embodiment 14 provides the method of any one of Embodiments 11-13, wherein the seeding occurs in a mammalian cell or mammalian-yeast hybrid. Embodiment 15 provides the method of Embodiment 14, wherein the mammalian cell or mammalian-yeast hybrid comprises DNA suitable for inducible expression of a Holliday Junction Recognition Protein (HJURP). Embodiment 16 provides the method of any one of Embodiments 10-15, wherein the method further comprises performing spheroplast fusion between a yeast cell comprising the one or more genomic loci, CENP-A, and a mammalian recipient cell. Embodiment 17 provides a cell comprising the human artificial chromosome (HAC) of any one of Embodiments 1-9. - 54 - 51854307.1 Attorney Docket No.046483-7423WO1(03465) Embodiment 18 provides a method of treating, preventing, and / or ameliorating a disease in a subject in need thereof, the method comprising administering to the subject the human artificial chromosome (HAC) of any one of Embodiments 1-9 or the cell of Embodiment 17. The terms and expressions employed herein are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the embodiments of the present application. Thus, it should be understood that although the present application describes specific embodiments and optional features, modification and variation of the compositions, methods, and concepts herein disclosed may be resorted to by those of ordinary skill in the art, and that such modifications and variations are considered to be within the scope of embodiments of the present application. - 55 - 51854307.1

Claims

Attorney Docket No.046483-7423WO1(03465) CLAIMS What is claimed is:

1. A human artificial chromosome (HAC) lacking repetitive centromere DNA, wherein the HAC comprises one or more genomic loci comprising a coding sequence and a non-coding sequence, wherein the one or more genomic loci comprise no more than one focus of CENP-A nucleosomes, and wherein the HAC replicates and segregates in a host cell independently of a natural chromosome of the host cell.

2. The HAC of claim 1, further comprising a sequence of chromosome 4, band 21, long arm (4q21 sequence).

3. The HAC of claim 2, wherein the 4q21 sequence comprises the focus of CENP-A nucleosomes.

4. The HAC of any one of claims 1-3, wherein the coding sequence comprises one or more sequences encoding one or more polypeptides.

5. The HAC of any one of claims 1-4, wherein the non-coding DNA sequence comprises about 760 kilobases (kb) or more.

6. The HAC of any one of claims 1-5, wherein the non-coding DNA sequence comprises a DNA sequence that shares at least 85% sequence homology with SEQ ID NO:

9.

7. The HAC of any one of claims 1-6, wherein the genomic loci further comprises one or more lactose operons (lacO).

8. The HAC of any one of claims 1-7, wherein the HAC comprises YAC Mm-4q21LacO(SEQ ID NO:).

9. The HAC of any one of claims 1-8, wherein the HAC further comprises a gene encoding a Holliday Junction Recognition Protein (HJURP). - 56 - 51854307.1Attorney Docket No.046483-7423WO1(03465) 10. A method for preparing the human artificial chromosome (HAC) of any one of claims 1- 9, the method comprising performing transformation-associated recombination (TAR) comprising a first vector comprising a region for acquiring CENP-A chromatin and a second vector comprising one or more genomic loci.

11. The method of claim 10, wherein the method further comprises seeding a CENP-A nucleosome on the region for acquiring CENP-A chromatin.

12. The method of claim 11, wherein the seeding comprises contacting the CENP-A locus with a Holliday junction recognition protein (HJURP).

13. The method of claim 12, wherein the first vector or second vector comprise DNA suitable for inducible expression of the HJURP.

14. The method of any one of claims 11-13, wherein the seeding occurs in a mammalian cell or mammalian-yeast hybrid.

15. The method of claim 14, wherein the mammalian cell or mammalian-yeast hybrid comprises DNA suitable for inducible expression of a Holliday Junction Recognition Protein (HJURP).

16. The method of any one of claims 10-15, wherein the method further comprises performing spheroplast fusion between a yeast cell comprising the one or more genomic loci, CENP-A, and a mammalian recipient cell.

17. A cell comprising the human artificial chromosome (HAC) of any one of claims 1-9.

18. A method of treating, preventing, and / or ameliorating a disease in a subject in need thereof, the method comprising administering to the subject the human artificial chromosome (HAC) of any one of claims 1-9 or the cell of claim 17. - 57 - 51854307.1

Citation Information

Patent Citations

  • Methods for cloning and manipulating genomes

    US20110053273A1

  • Human artificial chromosome (HAC) vector

    US20120093785A1